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Abstract
The m am m alian suprachiasmatic nucleus (SCN) of the hypothalamus is the site 
of a c ircad ian pacem aker tha t drives many rhythms of behaviour and 
physiology. The pacem aker displays a period of approxim ately 24 hours and can 
be entrained to external conditions by a variety of environmental cues. The 
principle entraining cue is the daily light-dark cycle  but other non-photic stimuli 
can also reset the phase. In rodents, the pacem aker is sensitive to photic 
influences during the night while non-photic stimuli are only e ffective  in resetting 
the pacem aker during the day. One afferent pa thw ay to the SCN originating in 
the m edian raphe nucleus contains serotonin (5-HT) and has been im plicated in 
the m ediation of non-photic phase shifting of the pacem aker. Disruption of this 
pa thw ay by neurotoxins can result in alteration of several parameters of 
c ircad ian rhythmicity. Application of 5-HT or its receptor agonists during the day 
results in phase advances of pacem aker period. A role for the neurotransmitter y- 
amino butyric ac id  (GABA) in c ircadian rhythmicity has also been shown. The 
GABAb recepto r agonist baclofen has been shown to phase advance  the 
pacem aker during the day in a m anner similar to 5-HT. Baclofen has also been 
shown to result in an increase in the release of newly synthesised 5-HT within the 
SCN area during the day. The substituted am phetam ine, 3,4- 
m ethylenedioxym etham phetam ine (MDMA) is a com m on drug of misuse as well 
as being a selective 5-HT neurotoxin. At neurotoxic doses it is known to result in 
degeneration of 5-HT terminal areas. In this study, the m agnitude of phase shifts 
due to daytim e injection of baclo fen to Syrian hamsters m aintained in constant 
darkness was com pared  before and after administration of a neurotoxic dose of 
MDMA. Immunohistochemical techniques were em ployed to quantify neurotoxic 
dam age  to the 5-HTergic terminal field within the SCN and cell bodies within the 
raphe nuclei. It was found tha t the m agnitude of bac lo fen  induced phase
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advances during the day were significantly greater than phase shifts induced by 
control injections of saline a t the same time. There was a significant d ifference 
betw een the m agnitude of phase advances to baclo fen  before and after 
treatm ent with MDMA. The difference in density of im m unohistochem ical 
staining for 5-HT was also different between MDMA treated  animals and 
untreated controls. These results imply there may be interaction between the 
GABAergic and 5-HTergic systems within the c ircad ian system for m ediation of 
non-photic phase shifting of the pacem aker during the day in rodents.
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1 Introduction
1.1 Circadian Rhythms
Circadian rhythms are bio logical cycles tha t follow a regular pattern of 
approxim ately 24 hours and are controlled by an endogenous pacem aker. They 
are manifest in numerous physiological and behavioural processes such as body 
tem perature, hormone levels and wheel running behaviour. The natural period 
of any individual an im al’s clock, or tau (x), is synchronised to environmental 
conditions by the process of entrainment. This involves the synchronisation of the 
c lock by environmental stimuli. The most predom inant stimuli, or zeitgeber, is light 
a lthough other non-photic stimuli also reset the phase of the clock.
M anipulation of the endogenous clock can be ach ieved  under laboratory 
conditions by m anipulation of environmental zeitgebers. The result of this can be 
observed as measurable changes in various physiological or behavioural 
processes, such as wheel-running activity in the case of laboratory animals. 
Through the removal of zeitgebers and establishment of constant environmental 
conditions, x can be measured from changes in these activ ity  patterns.
C ircadian time (CT) measures the state of the endogenous c lock under constant 
environmental conditions with CT12 being defined as the time of activ ity onset 
for nocturnal animals. Giving pulses of light a t different c ircad ian times results in 
phase shifts of the c lock reflected as changes in daily activ ity  patterns. The 
m agnitude and direction of these phase shifts varies depend ing upon the time 
a t which the light pulse is given. G raphically plotting time of day against phase 
shift produces in a phase-response curve (PRC) tha t varies slightly between 
species (Figure 1.1). For mammals, pulses given in the early subjective night result
i
in phase delays, in the late subjective night phase advances and during the 
subjective day no phase shift a t all (Dann and Pittendrigh 1976).
Non-photic stimuli are also capab le  of resetting the c ircad ian  clock. These 
include food availability (Mistlberger 1992), social interaction (Mrosovsky 1988), 
behavioural activ ity (Mrosovsky 1995), exposure to  a novel running wheel 
(Mrosovsky and Salmon 1987) and sleep deprivation (Antle and Mistlberger 
2000). The PRC is d ifferent from tha t seen in response to photic  stimuli, w ith phase 
advances during subjective day and very little e ffec t during subjective night 
(Figure 1.2).
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Figure 1.1 Photic phase response curve for the hamster. A pulse of light given early 
the c ircad ian night results in phase delays of c ircad ian rhythms, while pulses given 
late in the night result in advances.
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Figure 1.2 Examples of PRCs for three different non-photic stimuli. Each of these stimuli result 
in phase advances a t CT6. (From (Mrosovsky, Reebs et al. 1989).
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1.2 The Suprachiasmatic Nucleus
In mammals, the site of the pacem aker is the suprachiasmatic nucleus (SCN) of 
the hypothalamus (Meijer and Rietveld 1989; Moore 1995). For mammals, this is 
loca ted  above  the optic  chiasm and below the third ventricle. Lesions of the 
SCN result in the loss of rhythmicity in the animal (Rusak 1977). Cells of the SCN 
show circad ian rhythms of e lectrical activity (Gillette 1986) and this rhythmicity 
continues afte r isolation of the nucleus from other brain areas, indicating its 
endogenous nature. Electrical stimulation of the nucleus results in phase shifts of 
c ircad ian rhythms (Rusak and Groos 1982). Transplantation of SCN tissue from 
in tact to lesioned animals results in re-establishment of rhythmicity, with x being 
tha t of the donor animal (Ralph, Foster e t al. 1990). These studies would indicate 
that the SCN is involved in the generation of c ircad ian rhythms and in the 
absence of environmental cues or input from other brain areas, is capab le  of 
generating endogenous rhythms.
Despite the SCN being com posed of a relatively small number of cells, the 
neuropil is com plex with many synapse types. Axons enter the nucleus from all 
directions and dendrites extend outwith it. Some collaterals term inate on other 
neurones within the nucleus forming local circuits and some axons connec t the 
left and right nuclei (Van den Pol 1991). Several lines of evidence point to the 
SCN being com posed of subdivisions based upon cell size, afferent input or 
efferent output and transmitter content of neurone cell bodies (Card and Moore 
1982; Hoorneman and Buijs 1982; Van den Pol 1991). Two major subdivisions are 
the ventrolateral and dorsomedial regions with other subdivisions based upon 
immunostaining for cellular components. Afferent pathways synapse on the 
ventrolateral SCN where they form an extensive and com plex terminal field.
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There are three main afferent inputs conveying information on environmental 
conditions to the SCN. The retinohypothalam ic tract (RHT) is a monosynaptic 
tract originating in the retinal ganglion cells, which conveys pho tic  information 
predom inantly to the SCN (johnson, Morin et al. 1988). The 
gen icu lohypotha lam ic tract (GHT) runs from the thalam ic in tergeniculate leaflet 
(IGL) to the SCN (Morin, Blanchard et al. 1992) and is thought to convey non- 
photic information tha t acts to regulate photic stimuli (Albers and Ferris 1984). 
The IGL itself receives d irect input from the retina and this provides an indirect 
source of pho tic  information for the SCN (Morin 1994). Non-photic information is 
also received from the midbrain raphe nuclei (Meyer-Bernstein and Morin 1996; 
Leander, Vrang et al. 1998). There is evidence for a d irect neuronal projection 
from the retina to  the raphe (Shen and Semba 1994) but not tha t this synapses 
onto cells tha t pro ject to the SCN (Kawano, Decker et al. 1996).
1.3 Pharmacology of the Circadian System
In vitro  e lectrophysiological and pharm aco log ica l studies using isolated SCN 
slices dem onstrate the e ffec t on firing patterns of SCN neurones from application 
of agonists and antagonists of neurotransmitter receptors. In vivo 
pharm aco log ica l manipulations allow observation of changes in the timing of 
activ ity levels and thus interpretation of the state o f the internal clock. Alteration 
of either phase or period of the clock may occur through the d irect action of a 
drug on pacem aker cells. Alternatively, the site of action  for the drug may be in 
another brain area such as the raphe nuclei where it acts to  m odula te  afferent 
input to the SCN.
Several neurotransmitters and neuromodulators in the c ircad ian timing system 
utilise several receptor subtypes for com m unicating environm ental information.
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The excitatory am ino-acid  g lu tam ate is the principal neurotransmitter of the RHT 
(Ebling 1996), while non-photic stimuli a c t through the neuropeptide Y containing 
cells of the GHT (Card and Moore 1989) and serotonin (5-hydroxytryptamine or 5- 
HT), conta in ing cells of the raphe (Meyer-Bernstein and Morin 1996). The 
principle neurotransmitter of the SCN is y-aminobutyric ac id  (GABA) which is 
found along with its synthetic enzyme g lu tam ate decarboxylase (GAD) in 
virtually all SCN neurones (Moore and Speh 1993).
1.4 Serotonin
Serotonin is an indolealkylamine, also known as 5-hydroxytryptam ine (5-HT), 
synthesised from its dietary precursor the amino ac id  tryptophan. The synthetic 
reaction is catalysed by the enzyme tryptophan hydroxylase and  results in the 
production of 5-hydroxytryptophan (5-HTP). Tryptophan hydroxylase is 
synthesised in serotonergic nerve cell bodies and undergoes axonal transport to 
terminal areas where the majority of 5-HT synthesis takes p lace  (Meek and Neff 
1972). Decarboxylation of 5-HTP by the enzyme arom atic  L-amino acid  
decarboxylase results in the formation of 5-HT. O nce synthesised, 5-HT is 
accum ula ted  via a m em brane transporter in storage vesicles within nerve 
terminals. The mechanism of release is by exocytosis which is sensitive to  the 
sodium channel b locker tetrodotoxin (TTX) and to the presence of ca lc ium  ions, 
whether measured in vitro from brain slices (Carboni, C adoni et al. 1989) or in 
vivo  by microdialysis (Auerbach, Minzenberg e t al. 1989; Carboni and  Dichiara 
1989).
Release of 5-HT is known to be regulated by the action  of inhibitory 
autoreceptors, since release inhibition by 5-HT agonists was shown to  be blocked 
by the 5-HT antagonist methiothepin (Starke, Gothert et al. 1989). Serotonergic
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neurones have both som atodendritic and presynaptic autoreceptors, which 
differ in their pharm aco log ica l profiles. The som atodendritic autoreceptors 
suppress cell firing and are involved in collateral inhibition (Aghajanian 1981) as 
well as leading to reductions in synthesis and release of 5-HT in terminal areas. 
Presynaptic autoreceptors however are only involved in inhibition of 5-HT release.
The effects of synaptically released 5-HT are term inated by means of an 
reuptake process m ediated by a m em brane bound transporter protein (Graham 
and Longer 1992). In nervous tissue, 5-HT is m etabolised by the process of 
oxidative deam ination that is catalysed by the m itochondria l enzyme 
m onoam ine oxidase to produce 5-hydroxyindoleaceta ldehyde. This is rapidly 
oxidised by a ldehyde dehydrogenase to produce 5-hydroxyindoleacetic ac id  
(5-HIAA), which diffuses into the cerebrospinal fluid and  is e lim inated from the 
brain.
1.5 Anatomy of the Serotonergic System
Techniques used to e luc ida te  the anatom y of the 5-HT system have included 
neurotoxic lesioning; retrograde and anterograde tracing; autorad iography 
following in vivo  and in vitro app lica tion  of [3H]5-HT; and  immunohistochemistry 
for tryptophan hydroxylase or 5-HT.
The 5-HT system consists of a m orphologically diverse group of neurones with cell 
bodies loca ted  in the m idbrain raphe nuclei and some regions of the reticular 
form ation (Steinbusch 1981). There are tw o distinct subdivisions, a rostral division 
with cell bodies loca ted  in the m idbrain and rostral pons which projects to the 
forebrain and a cauda l division loca ted  in the m edulla ob longata  with 
descending projections to the spinal cord (Lidov and Molliver 1982). The rostral
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serotonergic division consists of the cauda l linear nucleus, the dorsal raphe 
nucleus (DR), the m edian raphe nucleus (MR), the B9 group and in primates a 
large dispersed group of cells loca ted  in the nucleus pontis oralis (Azmitia and 
Gannon 1986). The DR and MR together accoun t for approxim ately 80% of 
forebrain serotonergic terminals (Azmitia 1978).
The DR is loca ted  in the ventral part of the periaqueducta l grey m atter of the 
m idbrain and extends into the periventricular grey m atter of the rostral pons. It 
displays bilateral symmetry and has a diverse neuronal population, with the 
smallest cells on or near the midline and the largest cells in the most lateral and 
dorsal regions of the nucleus (Tork 1985). Several sub regions are distinguishable 
by differences in cell density, cell m orphology and area of projection (O'hearn 
and Molliver 1984; Waterhouse, Mihailoff e t al. 1986). The MR is found largely in 
the rostral pons with constituent cells arranged in tw o ad jacen t regions. Small 
cells with short dendrites are arranged around the midline and aligned parallel 
to the m id-sagittal plane. Outside the midline area the cells are loosely arranged 
w ithout any particular orientation and the boundary of this nucleus is not sharply 
defined (O'hearn and Molliver 1984; Tork 1985; Waterhouse, M ihailoff e t al. 1986).
The ascending serotonergic projections are extensive and conta in  many 
collaterals innervating diverse regions of the forebrain. These projections initially 
travel in the m edial forebrain bundle with axons extending from this to other fibre 
pathways and on to their target areas. There are tw o types of serotonergic axons 
in the forebrain (Kosofsky and Molliver 1987). The most com m on are thin, with 
fusiform shaped varicosities of less than 1 pm, which extend over large areas of 
the forebrain. These fibres tend to branch frequently with the branches being of 
the same structure as the parent fibres. The second fibre type has large round or 
oval varicosities on thin fibres and displays a beaded  appea rance  under the
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microscope. The varicosities are swellings in terminal areas tha t contain the 
vesicles responsible for 5-HT storage and release. Anterograde tracing studies 
have shown tha t the different axon types have different origins with the fine 
axons originating in the DR whiie the beaded axons arise in the MR (Kosofsky and 
Molliver 1987). Serial section analysis in the ca t has also dem onstrated tha t the 
two axon types form two independent fibre systems which m ay also have 
distinct functions (Mulligan and Tork 1988).
Within the c ircad ian system, a com bination of anterograde tracing, retrograde 
tracing and neurotoxic lesioning has shown tha t serotonergic innervation of the 
hamster SCN originates in the MR while that of the IGL originates in the DR 
(Meyer-Bernstein and Morin 1996). Additionally, some evidence  has been found 
in the rat, for a d irect serotonergic pathw ay to the SCN originating in the DR 
(Kawano, Decker e t al. 1996).
1.6 Serotonin in the Circadian System
Serotonin is thought to be involved in the transmission of non-photic information 
to the SCN. It is known tha t numerous types of non-photic stimuli are capab le  of 
adjusting the phase or period of c ircad ian rhythms in m am m alian species. 
Included am ong these are several which directly e ffec t serotonergic activity 
such as exercise or sleep deprivation. Wheel running activity, itself regulated by 
the c ircad ian system, can  m odulate oscillation of the clock in rodents indicating 
that certain behaviours could have a feedback  e ffec t on the clock. Sleep 
deprivation is also known to result in increased activ ity of 5-HT neurones within 
the raphe (Grossman, Mistlberger e t al. 2000). Within the SCN, release of 5-HT has 
been shown through microdialysis to be increased in the m id-subjective day by 
three hours of either wheel running or sleep deprivation, while wheel running at
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night results in reduction of 5-HT release (Dudley, DiNardo et al. 1998; Mistlberger, 
Antle et al. 2000). This pattern of release follows a similar pattern to the non- 
photic PRC of maximal phase advances during m id-subjective day and smaller 
delays during the night.
The e ffec t on c ircad ian rhythms of lesions of the raphe nuclei or chem ical 
disruption of 5-HT cells has been investigated in vivo  in a num ber of studies. 
Intraventricular administration of the 5HT-specific neurotoxin, 5,7- 
dihydroxytryptam ine (5,7-DHT), demonstrates tha t loss of serotonergic innervation 
to the SCN results in changes in the entrained rhythm of wheel running in the 
hamster (Smale, Michels et al. 1990; Morin and Blanchard 1991). Lesions of the 
MR (but not the DR) produce patterns of locom otor activ ity  similar to those 
resulting from the general intraventricular lesions (Meyer-Bernstein and Morin 
1996). In general, it was found tha t the rhythms b ecam e  irregular, had lower 
overall am plitude, an advanced  phase angle of entra inm ent and the active 
period within a c ircad ian cycle  was generally lengthened. The conclusion was 
drawn tha t 5-HT plays a m odulatory role tha t enhanced the stability of c ircadian 
rhythmicity.
Several experim ental techniques tha t result in reduced levels of 5-HT within the 
SCN have been used to investigate the involvem ent of 5-HT in non-photic phase 
shifting. In hamsters, the drug triazolam is thought to  phase shift the clock by 
inducing locom otor activity. This can be b locked by 5-HT deple tion  using the 
neurotoxins 5,7-DHT or p-ch loroam phetam ine (p-CPA) (Cutrera, Kalsbeek et al. 
1994; Penev, Turek et al. 1995; Meyer-Bernstein, Blanchard et al. 1997). However, 
other studies have shown tha t phase shifts induced by running in a novel wheel 
are una ffected  by 5,7-DHT lesions (Bobrzynska, G odfrey et al. 1996; Meyer- 
Bernstein, Blanchard et al. 1997). Administering a tryptophan-free d ie t to  animals
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results in a reduction of 5-HT release and when administered with three hours of 
sleep deprivation there was no e ffec t on phase shifts in the mid-subjective day 
(Mistlberger, Antle et al. 2000). However, inhibition of 5-HT synthesis using p-CPA 
com bined with ritanserin, a serotonin antagonist, does result in significant 
a ttenuation of phase shifts to sleep deprivation (Mistlberger, Antle et al. 2000). In 
mice, 5,7-DHT lesions elim inate entrainm ent to either restricted daily access to a 
home ca ge  wheel or forced running in a treadmill (Edgar, Reid et al. 1997; 
M archant, Watson et al. 1997). These results would ind ica te  tha t 5-HT plays an 
im portant role in the regulation of circad ian rhythms although its im portance 
m ay vary betw een species.
Techniques which can enhance 5-HT levels or activ ity within the SCN have also 
been used to investigate the involvem ent of 5-HT in non-photic phase shifting. 
The 5-HT antagonist WAY100635 increases 5-HT levels by blocking the actions of 
presynaptic inhibitory autoreceptors. When given systemically, this drug was 
found to increase levels of 5-HT within the SCN by approxim ately 50% as 
measured by in vivo  microdialysis, which is com parab le  to the levels produced 
by wheel running in the mid-subjective day (Antle, M archant e t al. 1998; Dudley, 
Dinardo et al. 1999). However, when administered a t this time, WAY100635 
neither induced phase shifts nor potentia ted  shifts induced by wheel running 
(Antle, M archant et al. 1998). Administration of the 5-HT precursor tryptophan 
can significantly increase 5-HT levels within the SCN during mid-subjective day by 
as much as 200% (Glass, Selim et al. 1995). This d id not induce significant phase 
shifts even when com bined with the 5-HT reuptake inhibitor fluoxetine, nor did it 
po tentia te  phase shifts induced by running in novel wheels.
Electrical stimulation of either the MR or the DR results in release of 5-HT within the 
SCN tha t is com parab le  to the levels released subsequent to injection of either
n
WAY100635 or tryptophan (Dudley, Dinardo et al. 1999). Electrical stimulation of 
either the MR or the DR during mid-subjective day also results in small phase 
a dvance  shifts (Meyer-Bernstein and Morin 1999). Since the pharm acological 
manipulations do not result in phase shifts even though they release the same 
am ount of 5-HT, it has been suggested tha t the shifts due to  electrical stimulation 
are not m ed ia ted  by 5-HT release within the SCN. It was also found tha t the 
general 5-HT antagonist metergoline was able to b lock the release of 5-HT in the 
SCN afte r e lectrica l stimulation of the DR but not the MR. Since the DR does not 
synapse on the SCN, it may be tha t these effects on 5-HT transmission are due to 
stimulation of 5-HT receptors on a direct pathw ay to the MR (Dudley, Dinardo et 
al. 1999; Meyer-Bernstein and Morin 1999).
If 5-HT is involved in the m ediation of non-photic phase shifts, then the use of 
agonists for the various 5-HT receptors should mimic these shifts. Direct 
m anipulation of c ircad ian rhythms can be achieved in vitro using isolated brain 
slice preparations conta in ing the SCN. Under these conditions, cells of the 
pacem aker genera te  c ircad ian rhythms of spontaneous e lectrical activity tha t 
can be phase shifted by exogenous stimulation. Application in a perfusate, of 
both 5-HT and the non-specific 5-HT agonist quipazine, results in phase advances 
during the m iddle of the subjective day and in delays during the m iddle of 
subjective night (Prosser, Miller et al. 1990; Prosser, Dean et al. 1993). These phase 
shifts were b locked by the non-specific 5-HT antagonist m etergoline, indicating 
the shifts were due to stimulation of 5-HT receptors. The phase shifts to quipazine 
were not b locked by the presence of TTX or high concentra tion  of magnesium 
ions, ind icating a d irect postsynaptic action on cells of the SCN (Prosser, Heller et 
al. 1992). Another study tha t app lied  the 5-HT agonists 8-hydroxy- 
d ipropylam inotetra lin (8-OH-DPAT) and 5-carboxam idotyptam ine (5-CT) by 
m icrodrop d irectly onto the ventrolateral SCN obta ined  different results
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(M edanic and Gillette 1992). Daytime advances were found to  be much larger 
by this m ethod while there was no e ffect of these drugs a t night. These 
differences in results suggest tha t serotonergic m odulation m ay be regionally 
specific within the SCN.
In vivo  studies have produced conflicting results with regard to the phase shifting 
effects of 5-HT agonists. Systemic administration of 5-HT agonists during mid- 
subjective day to both rats (Edgar, Miller et al. 1993) and hamsters (Tominaga, 
Shibata et al. 1992; Cutrera, Ouarour et al. 1994; Rea, Glass et al. 1994; Mintz, 
Gillespie e t al. 1997) has been found to induce phase advances. These shifts 
were found to be much smaller than those p roduced by three hour bouts of 
locom otor activ ity  or sleep deprivation, but similar to those from one hour bouts 
of wheel running in hamsters with blocked access to running wheels (Wickland & 
Turek, 1991). Administration during the night has been found to produce either 
no phase shift (Tominaga, Shibata et al. 1992; Edgar, Miller et al. 1993; Rea, Glass 
et al. 1994) or small delays (Tominaga, Shibata et al. 1992). O ther studies in the 
rat have shown tha t systemic administration of 5-HT agonists results in a PRC 
similar to tha t of pho tic  stimulation. This consists of phase delays in early 
subjective night, advances in late subjective night but with no phase shifts during 
the subjective day (Kennaway, Rowe et al. 1996; Kennaway and Moyer 1998; 
Kohler, Kalkowski e t al. 1999).
Localisation of the site of drug action is possible using in vivo  intra- 
cerebroventricular injection. In rats, injections to the SCN of either quipazine or 8- 
OH-DPAT induces phase advances during the day, but had no e ffe c t a t night 
(Edgar, Miller e t al. 1993). One study found injection of 8-OH-DPAT during the 
day, into the SCN of hamsters, induced slight advances (Challet, Scarbrough et 
al. 1998). Another found no e ffec t of injection to either the SCN or IGL of
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hamsters, but d id find advances when in jected into the raphe (Mintz, Gillespie et 
al. 1997). Yet another study found tha t SCN injection during the night in hamsters, 
of either 5-CT or 8-OH-DPAT resulted in no phase shift (Weber, Gannon et al. 
1998).
These inconsistencies betw een experimental results m ay be due to species 
differences (Kohler, Kalkowski et al. 1999) or even differences betw een strains of 
the same species (Kohler and Wollnik 1998). Alternatively, it is known that 
different 5-HT recepto r subtypes are expressed throughout the c ircad ian system 
and their response to exogenous stimulation varies, depend ing  upon the drug 
used and route of administration.
1.7 Serotonin Receptor Subtypes
Several 5-HT recepto r subtypes have been d iffe rentia ted by their 
pharm aco log ica l profiles and from the signal transduction mechanisms to which 
they are linked. All belong to the G prote in-coupled superfamily with the 
exception of the 5 -HT3 subtype, which is a ligand-gated ion channel. G protein- 
coup led receptors (GPCR) are mem brane bound proteins consisting of a single 
subunit with seven transmembrane regions. They function by coupling to 
members of a fam ily of m em brane bound proteins, the G proteins. Binding of 
agonist to GPCR results in activation of a G protein, regula ted by the binding of 
a guanyl nucleotide, and leads to stimulation of one or more mem brane 
effectors tha t m ediate  the cellular response. The effectors can  be ion channels 
or a lternatively enzymes that partic ipa te  in synthesis or deg rada tion  of second 
messengers tha t can influence a variety of cellular processes. These cellular 
effects have latencies measured in hundreds of milliseconds making them 
suitable for slow but sustained signalling or for m odula tion of fast
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neurotransmission. Within the circadian system, ana tom ica l ev idence exists for 
the presence of several of the 5-HT receptor subtypes.
Receptor binding studies using radio-ligands selective for d ifferent 5-HT 
receptors, ind ica te  tha t the 5 - H T ib receptor is present in the SCN of the rat 
(Prosser, Dean et al. 1993) and its gene expression has been confirm ed by in situ 
hybridisation (Roca, W eaver et al. 1993). C om bined e lectron microscope- 
immunohistochemistry exam ination of the SCN of the mouse indicates the 
presence of 5 - H T ib receptors associated with the plasma m em brane of retinal 
terminals (Pickard, Smith et al. 1999) although not a t the synaptic terminal zone 
(Belenky and Pickard 2001). High levels of mRNA for 5-HT2C receptors was found 
in the SCN by in situ hybridisation (Roca, W eaver e t al. 1993) and  subsequent 
im m unohistochem ical analysis found im m unoreactivity for both  5-HT2C receptors 
and to a lesser extent for 5-HT2A (Moyer and Kennaway 1999). In the hamster, 
im m unohistochem ical techniques have shown tha t the 5 H T sa recep to r is present 
in all four main com ponents of the circadian system, the SCN, IGL, MR and DR 
(Duncan, Jennes et al. 2000) with very high levels in the SCN (Oliver, Kinsey et al. 
2000). In neurones of the raphe nuclei, 5HT5A receptor-im m unoreactiv ity is found 
co-localised with 5HT-immunoreactivity, suggesting a functiona l role as 
presynaptic au to recep to r for regulation of 5HT neuronal activ ity  (Duncan, 
Jennes et al. 2000). Further analysis of this receptor is h indered by the lack of 
ligands selective for this particular subtype.
Two other 5-HT receptors tha t are thought to be present w ithin the circadian 
system are the 5 - H T i a  and 5-HTz receptors. The recently c loned  5-HTz receptor 
shares some pharm aco log ica l overlap with the 5 - H T i a  receptor, including high 
affinity for 8-OH-DPAT and 5-CT and there is some dispute as to  w hich of these 
receptors m ediate  the effects of serotonin within the SCN. An early
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autorad iographic study found high levels of [3H]8-OH-DPAT binding in the SCN of 
the rat and this was attributed to 5-HTia receptors (Prosser, Dean et al. 1993). 
O ther binding studies in the hamster have used [3H]8-OH-DPAT in conjunction 
with pindolol and ritanserin, antagonists for the 5-HTia and 5-HTz receptors 
respectively. These studies conc luded tha t 20 to 50% of receptor binding in the 
SCN is due to the 5-HT7 receptor, with the remainder being a ttributed to the 5- 
HTia recepto r (Duncan, Short et al. 1999; Rea and Pickard 2000). In the rat, use of 
[3H]5-CT as the radioligand failed to find binding for 5 -HT7 receptors in the SCN 
(Gustafson, Durkin et al. 1996) although another study used this m ethod 
successfully to identify binding in other areas of the rat brain (M engod, Vilaro et 
ai. 1996). In situ hybridisation in the rat found very little sign of gene expression for 
the 5-HTia recepto r in the SCN (Roca, Weaver e t al. 1993) while some evidence 
for the expression of the 5-HTz receptor has been found. One study using 
o ligonucleotide probes to rat 5-HTz receptor mRNA failed to d e te c t a 
hybridisation signal (Gustafson, Durkin et al. 1996), ano ther using ribonucleotide 
probes to different 5-HTz receptor isoforms did find low to m oderate  levels of 5- 
HT7 mRNA (Heidmann, Szot e t al. 1998) while the most recent de tec ted  high 
levels (Neumaier, Sexton et al. 2001). One study has d e te c te d  5-HTz mRNA in the 
hamster (Rea and Pickard 2000). Immunohistochemical staining in the rat failed 
to d e te c t im m unoreactivity for the 5-HTz receptor in the SCN (Moyer and 
Kennaway 1999), while another laboratory d e te c te d  prom inent staining co ­
localised with c-Fos im m unoreactivity (Neumaier, Sexton et al. 2001). In the 
mouse, 5-HTz im m unoreactivity is found throughout the rostrocaudal extent of 
the SCN (Belenky and Pickard 2001).
Several in vitro studies have im plicated 5-HTz receptors, in addition to or instead 
of 5 - H T i a  receptors, as mediators of 5-HT effects on SCN neurones. Advances in 
spontaneous e lectrical activ ity in the rat brain slice induced  by 8-OH-DPAT can
16
be b locked by ritanserin but not by pindolol (Lovenberg, Baron et al. 1993). 
Inhibition of GABAa responses by 5-HT and 8-OH-DPAT within the rat SCN was 
similarly antagonised by ritanserin, but not by pindolol (Kawahara, Saito et al. 
1994). Spontaneous neuronal firing rates in the hamster have been studied in 
vivo  and it was found tha t inhibition of firing by 5-HT, 5-CT and 8-OH-DPAT could 
be b locked by ritanserin but not by cyanopindolol (Ying and Rusak 1997).
1.8 Serotonergic Interactions with light
5-HT is thought also to a c t as a m odulator of photic phase shifting in the SCN. In 
vitro app lica tion  of the 5-HTib receptor agonist l-[3-(trifluoromethyl)phenyl]- 
piperazine (TFMPP), to the hamster hypothalam ic slice results in a reduction in 
the am plitude of op tic  nerve evoked excitatory post synaptic potentials 
(Pickard, Smith e t al. 1999). When systemically adm inistered in vivo, TFMPP 
attenuates the phase shifting effects of light as well as blocking the induction of 
Fos protein (an alternative marker for light stimulation), both  in the hamster 
(Pickard, W eber e t al. 1996) and in the mouse (Pickard and Rea 1997). These 
results a long with those from the anatom ica l studies would ind ica te  tha t these 
receptors function as modulators of g lu tam ate  release from RHT terminals.
The 5-HTia recepto r is present in the circad ian system both as presynaptic 
au to recep to r and postsynaptic heteroreceptor (Moriya, Yoshinobu et al. 1998). 
Systemic injection of the 5-HTia receptor antagonist WAY100635 results in 
augm entation of phase delays to light in early subjective night while having no 
effects on phase advances late a t night (Smart and Biello 2001).
There is some evidence suggesting that, in the rat, 5-HT m ay m odulate  light 
induced phase shifts through action a t 5-HT2C and /o r 5-HT2A receptors. Systemic
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injection of the 5-HT2A/2C receptor agonist (±)-l-(4-iodo-2,5-dimethoxyphenyl)-2- 
am inopropane hydrochloride resulted in delays in the rhythms of activity, 
melatonin secretion, and tem perature (Kennaway and Moyer 1998). This agonist 
also induced expression of the im m ediate early gene c-fos in a manner similar to 
light (Moyer and Kennaway 1999).
In v itro , the 5HTia/7 agonist 8-OH-DPAT reduces the am plitude of op tic  nerve- 
evoked excitatory post-synaptic potentials in SCN neurones from the mouse via 
a 5HT7 recepto r m ed ia ted  mechanism (Smith, Sollars e t al. 2001). The effects of 5- 
H T 7 antagonists on the expression of c-Fos expression has been exam ined in the 
rat. One study using m etergoline and ritanserin failed to prevent the photic 
induction of c-Fos in the SCN (Kennaway and Moyer 1998). Another showed that 
c-Fos expression induced by 5-CT and 8-OH-DPAT a t CT22 w ithout light, could be 
b locked by ritanserin in the presence of pindolol (Mullins, Gianutsos et al. 1999).
1.9 The Role of GABA in the Clock
y-am inobutyric ac id  (GABA) is an inhibitory neurotransmitter found extensively
throughout the central nervous system. It is synthesised in a single step from L- 
g lu tam ate, catalysed by the enzyme g lu tam ate  decarboxylase (GAD). A large 
num ber of SCN neurones conta in GABA as well as GAD (Card and Moore 1984; 
Van den Pol 1986; Moore and Speh 1993) and 48% of synaptic boutons in the 
SCN are GABAergic (Decavel and Van den Pol 1990). GABA has also been 
found co-localised in the SCN with other neurochemicals, such as vasoactive 
intestinal pep tide  in the ventrolateral SCN (Francois-Bellan, Kachidian et al. 1990) 
and arginine vasopressin in the dorsomedial SCN (Moore and Speh 1993). 
GABAergic interneurones comprise a dense network within the SCN (Moore and 
Speh 1993; Van den Pol 1993), including reciprocal innervation betw een each of
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the two nuclei (Buijs, Hou et al. 1994). GABAergic neurones comprise part of one 
afferent, the GHT, where they are co-localised with NPY (Van den Pol 1986; Card 
and Moore 1991; Moore and Speh 1993).
Several lines of ev idence ind icate  that the activ ity o f the GABAergic system is 
under c ircad ian control. GABA content in the SCN varies over the course of the 
c ircad ian cycle  showing a peak a t CT16 tha t can be entrained by the daily 
photoperiod and persists under conditions of constant darkness (Aguilar-Roblero, 
Verduzco-Carbajal e t al. 1993). GABA turnover rate also shows a peak at CT16 in 
several non-SCN areas of the central nervous system of Syrian hamsters 
(Kanterewicz, Rosenstein et al. 1995). GABAa recep to r sites in the brain show 
c ircad ian rhythms both in num ber and affinity (Wirz-Justice 1987) with a 
nocturnal peak in high affinity binding sites (Acuna-Castroviejo, Rosenstein et al. 
1986) which can be abolished by ablation of the SCN (Kafka, Marangos et al. 
1985). Finally, a mid to late night peak of rad ioactive  3H-GABA release was 
observed in hamster preoptic-m edia l basal hypotha lam ic explants (Yannielli, 
Kanterewicz et al. 1996).
A role has been suggested for GABA in the synchronisation of c ircad ian patterns 
of e lectrica l activ ity betw een individual cells of the SCN. Electrophysiological 
recordings from SCN cells in dissociated cell culture show tha t individual cells 
display diverse patterns in spontaneous electrical activ ity (Welsh, Logothetis et 
al. 1995). Application of GABA to dissociated SCN cells induces phase- 
dependan t phase shifts in the firing rhythm of individual cells and daily 
app lica tion  of GABA induces synchronisation of rhythms betw een the cells (Liu 
and Reppert 2000). Cellular com m unication via g ap  junctions has been shown in 
cell culture through dye coupling and this can be reduced by app lica tion  the
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GABAa recepto r agonist 3-hydroxy-5-aminoethylisoxazole hydrobrom ide 
(muscimol) to the culture medium (Shinohara, Hiruma et al. 2000).
1.10 GABA Receptor Subtypes
The effects of GABA are m ediated though several receptor subtypes. GABAa 
and GABAc receptors are both ionotropic receptors associated with Cl- 
channels. GABAa receptors have been identified within the SCN using 
autorad iographic (Francois-Bellan, Segu et al. 1989) as well as 
electrophysiological techniques (Liou, Shibata et al. 1990; Mason, Biello e t al. 
1991), while GABAc receptors were not found in the SCN using northern analysis 
techniques (O'Hara, Andretic et al. 1995). The third receptor subtype, the GABAb 
receptor, is a G-protein coup led m etabotrop ic recepto r (Bormann 2000). This is 
known to function presynaptically both as au to recep tor and heteroreceptor, as 
well as postsynaptically. Presynaptically, the GABAb receptor inhibits the release 
of neurotransmitter through suppression of C a2+ channels, while postsynaptically 
it functions to inhibit neuronal firing, m ediated by coupling to inwardly rectifying 
K+ channels. It is also recognised for inducing the inhibition of adenylyl cyclase 
activity, a cellular second messenger (Kerr and Ong 1995).
High affinity of the agonist 4-am ino-3-[4-chlorophenyl]-butanoic ac id  (baclofen) 
for GABAb receptors has been recognised for some time. However, there is 
differential selective antagonism with the currently availab le  antagonist ligands, 
ind icating the presence of different GABAb receptor subtypes (Jones, Tamm et 
al. 2000). Two genes are known that express two d ifferent receptors, GABAbi and 
GABAb2 (Kaupmann, Huggel e t al. 1997; Jones, Borowsky et al. 1998; White, Wise 
et al. 1998). When expressed individually in m am m alian cell lines or Xenopus 
oocytes, these were found to have similar antagonist binding properties to
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native GABAb receptors but have a much lower affinity for agonists. When 
exposed to agonist, neither is able to produce a cellular response, such as the 
opening of potassium channels (Kaupmann, Huggel e t al. 1997). When 
expressed alone GABAbi subunits were also found to  be dispersed within the cell 
cytoplasm and did not associate a t the cell surface (Couve, Moss et al. 2000).
Evidence tha t colocalisation of both receptor subtypes is required to  produce a 
functional GABAb recepto r comes from several sources. The distribution patterns 
for the expression of mRNAs of each subtype show substantial areas of overlap 
within the brain (Jones, Borowsky et al. 1998; Durkin, Gunwaldsen e t al. 1999; Lu, 
Ghasemzadeh et al. 1999). Co-expression studies illustrate that the 
pharm aco logy of the com bined protein unit is equ iva lent to tha t of native 
receptors and produces the expected responses from agonist or antagonist 
stimulation. Im m unoprecipitation studies show the subunits associate as 
heterodimers and tha t they are concentra ted  on the plasma m em brane (Jones, 
Borowsky et al. 1998; Kaupmann, Malitschek et al. 1998; White, Wise et al. 1998). 
The functional im portance of each of the individual subunits in this heterodimer 
remains to be discovered but it appears tha t there must be both a GABAbi and 
GABAb2 subunit present to produce a fully functional GABAb receptor. Several 
splice variants of each  of the two GABAb genes are known (Couve, Moss et al. 
2000). Different com binations of these variants m ay lead to pharm aco log ica l 
and functional differences due to substituted residues for ligand binding and G 
protein coupling (Bischoff, Leonhard et al. 1999; Charles, Evans et al. 2001). This 
may explain the appa ren t differences in baclofen effects be tw een pre- and 
postsynaptic sites. In cerebellum  for example, splice variant GABAbiq localisation 
is in agreem ent with a presynaptic role while tha t for another splice variant, 
GABABib favours a postsynaptic function (Kaupmann, Schuler e t al. 1998; Fritschy, 
Meskenaite et al. 1999).
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1.11 GABAb within the Circadian System
In situ hybridisation for both G A B A b i  (Lu, Ghasemzadeh et al. 1999) and G A B A b 2 
(Durkin, Gunwaldsen et al. 1999) mRNAs shows high expression of both subtypes 
within the SCN and the raphe nuclei of the rat. Immunohistochemical analysis of 
the G A B A b i  protein confirms this distribution while showing, by comparison with 
the distribution of GAD immunoreactivity, tha t this subunit is not expressed on 
GABAergic neurones. Some evidence was found however for expression of this 
recepto r on GABAergic interneurones in some areas of the rat brain (M argeta- 
Mitrovic, M itrovic et al. 1999).
Several lines of evidence ind icate tha t the stimulation of GABAb receptors results 
in m odulation of the phase shifting effects of light. In vitro, bac lo fen  strongly 
attenuates optic  nerve evoked SCN field potentials (Shibata, Liou e t al. 1986; 
Jiang, Allen et al. 1995) as well as the frequency of spontaneous miniature 
excitatory post-synaptic potentials (Jiang, Allen et al. 1995). The GABAb 
antagonist 3-Amino-2-(4-chlorophenyl) propylphosphonic ac id  (phaclofen) dose 
dependently  increases SCN field potentia l amplitudes in vitro (Gannon, C ato  et 
al. 1995). Systemically administered baclofen has been reported to  a ttenua te  
both light-induced phase advances and delays of the running activ ity rhythm in 
hamsters (Ralph and M enaker 1989), as well as light-induced expression of c-fos 
(Colwell, Kaufman et al. 1993). M icroinjection of baclofen directly to the SCN 
reduces both the phase delaying and advancing effects of light (Gillespie, Mintz 
et al. 1997) as well as reducing the am ount of c-fos im m unoreactivity within the 
SCN (Gillespie, Van Der Beek et al. 1999). The GABAb antagonist 3-amino-propyl 
(diethoxymethyl)phosphinic ac id  (CGP 35348) increases the phase delaying 
e ffect of light a t CT14, while having no e ffec t on phase advances to  light at
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CT19 (Gillespie, Mintz et al. 1997), or on induction of c-fos protein a t either time 
point (Gillespie, Van Der Beek et al. 1999).
Stimulation of GABAergic transmission via GABAb receptors can  also have a 
d irect e ffec t on the clock. In vitro work indicates tha t app lica tion  of baclofen to 
the SCN slice results in phase advances of the rhythm of e lectrica l activity of SCN 
cells a t zeitgeber time (ZT) 6 and small delays a t ZT22 (Biggs and Prosser 1998), 
where ZT12 is the time of lights off in the animal co lony under a light-dark cycle. 
Administration of TTX blocks both these phase advances and delays suggesting 
tha t the GABAb receptors m ediating these phase shifts must be loca ted  
presynaptically a t least one neurone aw ay from the pacem aker cells (Bergeron, 
Danielson et al. 1999). Application by m icroinjection of baclo fen directly to the 
SCN also phase advances the clock a t CT6 (Smith, Turek e t al. 1990). The ability 
of GABAb receptors to phase advance  the clock during the day, indicates tha t 
they m ay be involved in the m ediation of non-photic input to the SCN, since this 
is a time when non-photic stimuli also phase advance  the pacem aker.
1.12 Interactions between GABAb and Serotonin
There is ev idence for interaction between GABAergic and serotonergic 
transmissions within the SCN. Double-labelling techniques using [3H]5-HT uptake 
rad ioautography com bined  with immunohistochemistry for GAD found a close 
in terconnection betw een these two afferent systems (Bosler 1989). No axonal 
varicosities showed double labelling for both transmitter types, indicating 
separate neuronal populations and 41% of the 5-HT terminals were directly 
apposed, on a post-synaptic target, to a t least one GAD-imm unoreactive 
profile. It is also known tha t administration of GABAb but not GABAa agonists
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increases the release of serotonin within the SCN in vitro (Francois-Bellan, Hery et 
al. 1987) as well as in vivo  (Francois-Bellan, Hery et al. 1988).
GABAb receptors are also known to be present within the raphe nuclei (Lu, 
Ghasemzadeh et al. 1999; M argeta-M itrovic, Mitrovic et al. 1999). One study 
utilised in situ hybridisation to examine coexpression of mRNAs for GAD, the 
GABAbi subunit and the 5-HT transporter (Abelian, Adell e t al. 2000). It was found 
that most 5-HT neurones in both nuclei expressed the GABAbi transcript while 
very few  cells conta ined  the transcript for GAD. This is confirm ed in both nuclei 
by double labelling immunohistochemistry for GABAb receptors and 5-HT (Varga, 
Sik e t al. 2002). This study found colocalisation in virtually all serotonergic cells. 
Electron-m icroscopic exam ination also revealed tha t staining for GABAb 
receptors appeared  on proximal dendrites and cell bodies, never on afferent 
axons.
The effects of GABAb recepto r stimulation in the raphe nuclei have been 
investigated using microdialysis and electrophysiological techniques (Tao, Ma et 
al. 1996; Abelian, Adell e t al. 2000; Abelian, Jolas e t al. 2000). It was found that 
both presynaptic and postsynaptic effects of GABAb recepto r stimulation could 
be found within the raphe. Higher concentrations of baclo fen are required to 
stimulate the postsynaptic effects and GABAb antagonists fail to fully block the 
effects of baclo fen. This would indicate that the different effects of baclofen 
m ight be m ed ia ted  by different populations of GABAb recepto r subtypes a t pre 
and postsynaptic sites. Microdialysis also showed tha t there is a time of day 
e ffect of baclo fen administration to the DR. Local administration of the drug 
results in a reduction of released 5-HT during lights-out conditions (Tao, Ma et al. 
1996) while having the opposite e ffect during lights-on conditions (Abelian, Jolas
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et al. 2000). Local injection of baclofen to the MR results in an increase of 
released 5-HT (Abelian, Adell e t al. 2000)
1.13 Molecular Components of the Circadian Clock
Details of how circad ian rhythms are generated in mammals a t the molecular 
level com e mainly from studies in mice. The mechanism for generating rhythms 
over a 24-hour period depends upon interwoven positive and  negative 
transcriptional/translational feedback  loops of specific c lock genes within cells 
of the SCN (Figure 1.3). These genes include the period (Per/, Per2 and Per3), 
c ryptochrom e (Cry/ and Cry2), C lock  and BmalJ (brain and muscle Arnt-like) 
genes. In animals with ta rgeted disruption of either Perl or Per2 but not Per3 
gene, locom otor activ ity rhythms are severely disrupted (Bae, Jin e t al. 2001), 
and m ice defic ien t in both Per/ and Per2 do not express c ircad ian  rhythms 
(Zheng, A lbrecht e t al. 2001). The PerOl m utant of Drosophila, which is arrhythmic 
due to a lack of endogenous PER, can have rhythm icity restored by the 
introduction of m am m alian Per/ or Per2 genes (Shigeyoshi, Meyer-Bernstein et al. 
2002). A key role is also p layed by C ry/, Cry2 and Bm all since C ry l/C ry2  double 
knockout m ice (Okamura, Miyake et al. 1999; Van der Horst, Muijtjens et al. 1999) 
and Bm all knockout m ice (Bunger, Wilsbacher et al. 2000) show the im m ediate 
loss of a behavioural rhythm in constant darkness.
A positive loop is form ed by heterodimers of the CLOCK and BMAL1 proteins 
which bind to E-boxes loca ted  in the regulatory region of Per and  Cry genes and 
initiate their transcription (Gekakis, Staknis e t al. 1998; Hogenesch, Gu et al. 1998; 
Yam aguchi, Mitsui et al. 2000; Lee, Etchegaray e t al. 2001; Travnickova-Bendova, 
Cermakian et al. 2002; Etchegaray, Lee et al. 2003). Accum ulation  of Per mRNA 
peaks in the SCN during the subjective day, while translation to PERI and PER2
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proteins occurs in the cytoplasm where concentrations peak during the middle 
of the night (Albrecht, Sun et al. 1997; Shearman, Zylka et al. 1997; Tei, Okamura 
et al. 1997; Zylka, Shearman et al. 1998). A negative loop is then form ed by the 
translocation of these proteins to the nucleus where they form stable complexes 
with CRY1 or CRY2 and suppress the transcription of Perl and Per2 genes by 
binding to the CLOCK/BMAL1 heterodim er (Kume, Zylka et al. 1999). (Figure 1.3).
The above  core feedback  loop is very stable and accurate ly maintains a 24 h 
rhythm. There are other com plem entary m olecular loops assisting this core 
feedback  loop a t the gene-transcription level. Another feedback  loop is formed 
when the CLOCK/BMAL1 heterodim er activates a gene encod ing  the orphan 
nuclear recepto r REV-ERBa. This is a transcription fac to r tha t functions to repress 
the B m a ll ,  C lock  and C ry l  genes (Onishi, Yam aguchi e t al. 2002; Preitner, 
Damiola e t al. 2002; Ueda, Chen et al. 2002; Etchegaray, Lee et al. 2003). Two 
other transcription factors thought to be involved in the m olecular clockwork are 
DEC1 and DEC2. These have been shown to be expressed in the SCN and inhibit 
the activ ity of the CLOCK/BMAL1 dimers either through association with them or 
through com petition  with the E-box elements of the ta rge t genes (Honma, 
Kawam oto et al. 2002).
Post-translational mechanisms are involved in regulating levels of c lock proteins 
both spatially and tem porally through phosphorylation, degradation  and 
nuclear translocation. The casein kinases (CKI) 8 and e have been shown to 
phosphorylate PERI, PER2, CRY1, CRY2 and BMAL1 (Keesler, C am acho  et al. 
2000; Lowrey, Shimomura et al. 2000; C am acho, Cilio et al. 2001; Eide, Vielhaber 
et al. 2002). Phosphorylation by CKI serves both to a llow transport of the clock 
gene proteins into the nucleus as well as allowing their eventual degradation. 
The PER2 protein usually shuttles between the cytoplasm and the nucleus and is
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easily deg raded  by ubiquitination and the proteasom e pa thw ay (Yagita, 
Tamanini e t al. 2002). It is also known tha t the ubiquitination of PER proteins is 
inhibited in the presence of CRY proteins and the PER proteins appear to be 
more fragile if they do not dimerize with CRY proteins. It has also been recently 
dem onstrated tha t the CRY protein, which is a strong suppressor of Per? 
transcription, can be ubiquitinated when PER proteins are absent (Yagita, 
Tamanini et al. 2002). The decrease of PER in the nucleus due to  proteasome- 
dependent degradation  causes destabilisation of CRY, and the decrease in CRY 
will lead to the re-starting of Perl and Per2 gene transcription.
1.14 Entrainment
Entrainment of the m olecular clock to both pho tic  and non-photic stimuli 
involves transcriptional mechanisms that alter Per gene expression in the SCN. 
Light pulses lead to increased levels of Perl and Per2 in the SCN (Albrecht, Sun et 
al. 1997; Shearman, Zylka et al. 1997; Shigeyoshi, Taguchi e t al. 1997) while 
intracerebroventricular injections of antisense oligodeoxynucleotides to Perl 
inhibit light-induced phase delays in m ice (Akiyama, Kouzu et al. 1999). Mice 
with a m utated Per? gene exhibit altered light induced phase advances, while 
Per2 m utant m ice display impaired light-induced phase delays (Albrecht, Zheng 
et al. 2001). Entrainment by non-photic cues has been shown to be as a result of 
reduction o f Per expression within cells of the SCN. Both NPY and novel wheel 
running activ ity can decrease Per? and Per2 mRNA levels in vivo (Maywood, 
Mrosovsky et al. 1999; M aywood, Okamura et al. 2002) and in vitro (Fukuhara, 
Brewer et al. 2001). Systemic injections of 8-OH-DPAT and short-acting 
benzodiazepines suppress Per? and Per2 levels in the SCN of hamsters (Horikawa, 
Yokota e t al. 2000; Yokota, Horikawa et al. 2000).
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Outwith the laboratory environment it is unlikely tha t photic and non-photic 
stimuli occur in isolation from each other and it has been shown tha t there is 
interaction betw een the two. Light pulses given shortly a fte r a non-photic 
stimulus reduce the phase advances tha t would otherwise have been 
produced. This occurs when the non-photic stimulus is running in a novel wheel 
(Mrosovsky 1991), injection o f NPY (Biello 1995), or in jection of 5-HT agonists 
(Penev, Zee et al. 1997). The opposite has also been found w ith phase shifts to 
light being a ttenua ted  by activ ity (Ralph and Mrosovsky 1992), novel wheel 
running (Mistlberger and Antle 1998), injection of NPY (Weber and Rea 1997) or 
injection of 5-HT (Weber and Rea 1997). It has also been shown tha t the 
reduction in levels of PER expression produced by novel w heel running can be 
a ttenua ted  by a light pulse given im m ediately following the non-photic pulse 
(M aywood and Mrosovsky 2001).
1.15 Output pathways of the SCN
The core c ircad ian clock regulates the tem pora l variation of numerous 
behavioural and physiological processes. The oscillations of gene expression in 
the m olecular c lock must be translated into a form tha t will im part rhythmicity to 
these other processes. Rats whose SCN neuronal firing has been inhibited with 
the sodium channel blocker TTX display arrhythm ic behaviour patterns and 
rhythm icity is restored a t the previous c ircad ian  phase on removal of TTX 
treatm ent (Schwartz, Gross et al. 1987; Schwartz 1991). A similar result is achieved 
using individual SCN neurons treated with TTX in vitro (Welsh, Logothetis et al. 
1995) suggesting tha t the rhythmic e lectrical activ ity  of SCN cells is an output of 
the c lock and not a com ponent. The neuropeptide  arginine vasopressin (AVP) 
has been shown to augm ent the m agnitude of the e lectrica l activ ity  rhythm in 
the SCN through a receptor-m edia ted excitation of SCN neurons (Mihai,
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Coculescu et al. 1994). Expression of A VP is directly regula ted by CLOCK/BMAL1 
heterodimers acting  on an E-box within its prom oter region and its transcription is 
negatively regulated by the same molecules tha t negatively regulate the core 
clockwork (Jin, Shearman et al. 1999; Kume, Zylka et al. 1999). M ice with 
mutations in the Per2 gene show loss of the rhythmic expression of the AVP gene 
in the SCN ind icating c ircad ian control of AVP gene expression within the SCN 
(Albrecht, Zheng et al. 2001).
Another mechanism by which the clock controls downstream events is to  use the 
protein products of clock-controlled genes tha t are regulated by the core 
feedback  loops. One such protein is D-element binding protein (DBP) tha t is 
expressed with a c ircad ian period (Wuarin and Schibler 1990) and which has 
been shown to be regulated by CLOCK/BMAL1 heterodimers (Ripperger, 
Shearman et al. 2000). DBP is a transcription fac to r tha t can bind to  the prom oter 
of the Perl gene and positively influence Perl transcription (Yamaguchi, Mitsui et 
al. 2000) ind icating the clock can react to its own targe t genes and  thus sense 
the physiological state of the organism. A num ber of other genes are controlled 
by DBP including Cyp2a4  and Cyp2a5  the protein products of which are 
involved in the metabolism of the sex hormones testosterone and  estradiol 
(Lavery and Schibler 1993; Lavery, Lopez-Molina et al. 1999). A m utation in the 
D bp  gene shortens circad ian period and affects c ircad ian sleep consolidation 
and rhythmic e lectroencephalogram  activ ity (Franken, Lopez-Molina e t al. 
2000).
It has been shown tha t diffusible, secreted molecules from the SCN can  control 
rodent activ ity rhythms. Hamsters carrying the tau m utation, which shortens the 
c ircad ian period, were given bilateral lesions of the SCN. Subsequent to this, a 
w ild-type SCN was im planted within a semi-permeable polym etric capsule in the
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third ventricle of the lesioned animals. The capsule prevents neural outgrowths 
from the im p lanted SCN while still allowing diffusion of humoral signals. It was 
found after several weeks tha t the locom otor rhythm displayed by the im planted 
animals was tha t of the w ild-type phenotype (Silver, LeSauter e t al. 1996). The 
peptide, transforming growth fac to r a (TGFa), is expressed in a c ircad ian fashion 
in the SCN of hamster and com plete ly blocks wheel-running activity when 
infused into the third ventricle. The receptor for TGFa is the epiderm al growth 
fac to r recepto r and this is expressed in the subparaventricular zone, a major 
target region of the SCN. Animals with mutations in this receptor display 
increased wheel running activ ity during the day and an imprecise onset of 
nocturnal activ ity (Kramer, Yang et al. 2001). Another cand ida te  c lock output 
signal is prokineticin 2 (PK2) tha t is expressed in the SCN in a c ircad ian fashion. Its 
transcription is ac tiva ted  by CLOCK/BMAL1 via an E-box in the PK2 prom oter and 
inhibited by the PER and CRY proteins. The circad ian pattern of PK2 expression is 
shifted in response to light resetting of the c lock and wheel running activity is 
suppressed when the protein is infused into the third ventricle during the night. 
The recepto r for PK2 is present in the SCN and in m any ta rge t regions of SCN 
efferents (Cheng, Bullock et al. 2002).
1.16 3,4-methylenedioxymethamphetamine (MDMA)
The am phetam ine derivative 3,4-m ethylenedioxym etham phetam ine (MDMA), 
also known as ecstasy is known to have both acute  and chronic toxic effects in 
animals and humans. First synthesised and pa ten ted  in 1914 for use as an 
appe tite  suppressant it has becom e increasingly popular as a recreational drug. 
It is used primarily by young people  in large dance  settings, or ‘raves' but is also 
known to be used in smaller social gatherings. Users report tha t a fter abou t 20 
minutes the drug begins to produce euphoria, feelings of intim acy towards
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others, heightened arousal, increased self-confidence and increased sensory 
sensitivity (Morgan 2000). Acute adverse physiological symptoms reported 
include tachycard ia , bruxism, trismus, pupilary dilation, ga it instability, nausea, 
suppressed appe tite  and hyperthermia (Morgan 2000). Users report subsequent 
to 24 to 48 hours of these effects, there follows a period characterised by muscle 
aches, fatigue, depression, irritability, difficulty in concentra ting  and headache 
(Morgan 2000). The most adverse acute  effects of MDMA a ppea r to be related 
to hypertherm ia. This is typically accom pan ied  by a num ber of clin ical problems 
including seizures, intravascular coagulation, rhabdomyolysis, renal and liver 
im pairm ent (Gowing, Henry-Edwards et al. 2002). The toxicity of the drug can be 
enhanced under certain conditions such as those present a t a rave. A 
com bination of the d irect effects of MDMA, high am bient tem perature, 
sustained physical activ ity and inadequate  fluid rep lacem ent all impair 
tem perature regulation and can even lead to dea th  (Gowing, Henry-Edwards et 
al. 2002).
MDMA has been shown to cause long-term neurotoxicity in animals. Studies 
ind ica te  tha t the drug is toxic to serotonergic systems and to a lesser extent 
dopam inerg ic systems (Burgess, O 'Donohoe et al. 2000). A single dose of MDMA 
(40 m g/kg) in rats results in decreased levels of both 5-HT and 5-HIAA within three 
days and which lasts for up to eight weeks (Commins, Vosmer e t al. 1987). After 
multiple doses (5-20 m g/kg, tw ice  daily over 4 days), the decreases last from 6 to 
12 months (Battaglia, Yeh et al. 1988). These reductions vary regionally within the 
brain with severe reductions in the neocortex, striatum and hippocam pus, while 
smaller decreases were found in the brainstem and hypothalam us (Stone, Stahl 
et al. 1986; Battaglia, Yeh et al. 1987). The num ber of 5-HT uptake transporter sites 
was found to be reduced in rat brain after administration of MDMA from studies 
using both autorad iography (Battaglia, Yeh et al. 1987) and synaptosomal
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preparations (Commins, Vosmer et al. 1987; Schmidt 1987). These results are 
consistent with the degeneration of presynaptic terminal areas.
Immunohistochemical techniques demonstrate that MDMA administration results 
in loss of fine serotonergic axons throughout the forebrain of the rat (O'Hearn, 
Battaglia et al. 1988), with the areas of fibre reduction being similar to those for 
the loss of transporter sites (Battaglia, Yeh et al. 1987). Fibres which suffer the loss 
of terminal areas are of the fine fibre type tha t originate in the DR while the thick 
beaded  axons of the MR are spared from dam age  (Molliver, Berger et al. 1990). 
The cell bodies within the raphe remain im m unoreactive ind icating a lack of 
degeneration (O'Hearn, Battaglia et al. 1988). The sparing of cell bodies from 
dam age  suggests the potentia l for regeneration of serotonergic projections and 
this does occur in both rodents and non-human primates, but the pattern of 
regeneration is generally abnorm al (Fischer, Hatzidimitriou et al. 1995).
The effects of MDMA on c ircad ian timing have been addressed in two previous 
studies. One in vitro experim ent found tha t pre-treatm ent w ith MDMA resulted in 
a reduced ability of cells of the SCN to phase shift to the 5-HT agonist 8-OH-DPAT 
(Biello and Dafters 2001). In vivo the ability of the SCN to phase shift to both light 
and 8-OH-DPAT was shown to be significantly reduced subsequent to MDMA 
administration (Colbron, Jones et al. 2002).
1.17 The Study
It is known tha t 5-HT or its agonists can phase advance  the c ircad ian pacem aker 
a t ZT6 in vitro (Prosser, Miller et al. 1990). Likewise, stimulation of GABAb receptors 
during the day can phase shift the pacem aker both in vitro (Biggs and Prosser 
1998) and in vivo (Smith, Turek e t al. 1990). It is also known tha t the stimulation of
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GABAb receptors during the subjective day increases the release of newly 
synthesised 5-HT within the SCN area (Francois-Bellan, Hery e t ai. 1987). It may be 
tha t the baclo fen induced phase shifts are brought abou t via the increased 
release of 5-HT within the SCN.
The following experiments were carried out to investigate w hether the in vivo 
stimulation of GABAb receptors a t CT6 results in a phase a dvance  shift in the 
c ircad ian pacem aker as seen in vitro. The involvem ent of 5-HT in the baclofen 
induced phase shifts was investigated by lesioning of serotonergic input to the 
SCN using the neurotoxin MDMA. Finally, the ana tom ica l effects of MDMA 
treatm ent were investigated in both the SCN and the raphe nuclei using 
im m unohistochem ical techniques.
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2 Materials and Methods
2.1 General Procedures
All work was carried out in accordance  with local codes of p rac tice  and within 
the framework of the Animals (Scientific Procedures) Act of 1986. Adult male 
Syrian hamsters [Mesocricetus auratus), 100-130g, (Harlan Sprague-Dawley, 
Oxon, UK). Animals were housed individually in polypropylene cages ( 1 3 x 9 x 8  
cm) with food and w a ter availab le a d  libitum. Cages were fitted with a 16 cm 
running wheel a tta ch ed  to a micro switch which was m onitored continuously by 
Dataquest Pro-Data software (Data Sciences Inc., Roseville, MN, USA), with 
wheel running activ ity gathered in 10-minute bins. Animals were initially 
acclim atised for a minimum period of 5 days a t 22 ± 2°C and light:dark cycle  of 
12:12 (LD 12:12). Subsequent to this, constant environm ental conditions (DD) 
were established by switching off the animal room lights. Alternatively, the 
animals were transferred to a ventilated, light-tight cham ber, measuring 174 x 87 
x 56 cm  with the lights turned off. Both room and cab ine t were illuminated by 
dim red light (14-18 lux) to enable daily husbandry practices to  be carried out. 
This level and w ave length  of illumination has been shown to  be ineffective in 
resetting the phase of the endogenous clock of hamsters (Biello 1995). All 
animals were left in DD for a minimum of 7 days to establish free-running 
conditions within the c lock before any drug treatments were given.
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2.2 Behavioural Analysis
2.2.1 Activity Onset
Activity onset (CT12) was taken as the first period of activ ity closest to the time of 
lights out from the most recent LD cycle. For the purposes of statistical analysis, 
CT12 was defined as the first 10-minute bin of greater than 50 wheel revolutions 
followed by a subsequent bin of greater than 50 revolutions within a 30-minute 
period. Activity onset for the day of drug treatm ent was ca lcu la ted  by forward 
regression of the line of best fit for the activity onsets of the 7 days prior to the 
treatm ent. Any animals with less than five d a ta  points for the regression 
ca lcu la tion  were excluded from the analysis.
To ca lcu la te  the regression line, the times for CT12 were taken from the raw data  
files genera ted by the Dataquest software. Each of these was converted to a 
decim al figure by expressing minutes past the hour as a fraction of 60 and was 
then entered onto a Microsoft Excel tem plate  (Figure 2.1). Excel then 
autom atica lly  ca lcu la ted  the line of best fit and produced a graph for these 
da ta  points (Figure 2.2) along with the equation of the line in the form of y = 
mx+c. The time of activ ity onset for the day of drug administration was 
ca lcu la ted  by substituting 8 (for the 8th day) for 'x' into the equation of the 
regression line and converting back from the decim al. The time of drug 
administration (CT6) was 6 hours before the p red icted onset of activity.
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2.2.2 Phase Shifts in Activity Onset
Post-drug treatm ent activ ity onsets were ca lcu la ted  by backw ard  regression of a 
line of best fit for the activ ity onsets of 7 days post-treatm ent. The initial 3 days 
post-treatm ent were excluded from the regression calculations to allow for 
transient effects. Any animals with less than five d a ta  points for the regression 
ca lcu la tion  were excluded from the analysis. The m ethod of ca lcu la tion  was by 
a similar m ethod to tha t used for the ca lcu lation of activ ity onset. The values for 
CT12 were taken, converted to decimals and entered onto the Excel tem plate 
(Figure 2.3) to p roduce a similar graph to tha t described above. This time 
however, the value of 10 was entered for 'x' into the ca lcu la ted  equation of best 
fit. The resulting value for activ ity onset was entered into the tem plate. Phase 
shifts were ca lcu la ted  as the d ifference between pre-treatm ent and post­
treatm ent activ ity onsets (Figure 2.4).
2.2.3 Changes in I
The values of x were taken directly from the regression lines p roduced  in Excel for 
ca lcu la ting  activ ity onset. The value of x is simply the grad ient of these lines i.e. 
the 'm ' in y = mx + c. Changes in x subsequent to administration of baclofen 
were com pared  betw een animals before and afte r MDMA treatm ent.
2.2.4 Changes in Activity Offset
Activity offset was defined as the time point a t which the 98th percentile of the 
total activ ity for the c ircad ian day is reached. This has been empirically 
determ ined to be the least variable ind icator of activ ity offset (Meyer-Bernstein 
and Morin 1996). Total daily activ ity was taken to be all w heel running activity
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tha t fell betw een the times of activ ity onset for two consecutive days. The time 
of the da ta  bin in which 98% of this figure fell, was then taken as the time of 
activ ity offset. The time of activ ity offset for all seven days prior to the day of drug 
treatm ent were then determ ined. These times were then converted to decim al 
and entered into the Excel tem plate  as described above. The tem plate  then 
ca lcu la ted  the time for activ ity offset on the day of drug treatm ent by forward 
regression. The times for activ ity offset for seven days post-drug treatm ent were 
then ca lcu la ted  by backwards regression. The three days im m ediately following 
drug treatm ent were excluded from this ca lcu lation to allow for transient shifts. 
Any animals for which there were less than five d a ta  points for either of the 
regression calculations were excluded from the calculations. Differences in 
activ ity offset were taken as the difference betw een the results of the two 
regression calculations.
2.2.5 Alpha Activity Period
The a lpha activ ity period was taken as the time, in minutes, between the times of 
activ ity onset and activ ity offset. The mean figure for each  animal was used in 
analysis.
2.2.6 Total Activity
Total daily activ ity  was taken to be all wheel running activ ity  that fell between 
the times of activ ity onset for two consecutive days. The m ean figure for each 
animal was used in analysis.
3?
2.3 Drug treatments
After 7 days in DD, each  animal (n=16) received an intraperitoneal (i.p.) injection 
of R(+)-baclofen hydrochloride (10 m g/kg in 0.9% saline; Sigma, Poole, UK) a t CT 
6. Animals rem ained in DD for 10 days before receiving an i.p. in jection of 0.9% 
saline a t CT6. Following a further period of 10 days in DD, all animals were 
transferred into a cycle  of LD 14:10. Subsequent to 7 days under the LD cycle, all 
animals rece ived a subcutaneous injection of 3,4- 
m ethylenedioxym etham phetam ine (MDMA; kindly dona ted  by the National 
Institute of Health, USA) in 0.9% saline, from 3 to 4 hours prior to lights off. This drug 
was adm inistered in increasing doses of 10 m g/kg, 15 m g/kg and 20 m g/kg over 
three consecutive days. Animals remained in LD 14:10 for a further 12 days 
before being returned to DD. After 7 days in DD a second i.p. injection of 
baclofen was adm inistered a t CT6 followed by 10 days in DD and a final 
injection of saline a t CT6. All injections with the exception of those of MDMA 
were carried out under dim red light (14-18 lux).
2.4 Immunohistochemistry
2.4.1 Monoclonal Antibody to Serotonin
The an tibody used in this study was purchased from A ccura te  Chem ical and 
Scientific Corporation, Westbury, New York, U.S.A. (Product num ber YMC1019; 
Rat anti-serotonin; Cell line YC5/45). This m onoclonal an tibody was secreted by a 
hybridom a form ed by the fusion of a Y3-Ag-1.2.3 rat myeloma cell w ith a spleen 
cell from a male COB Wistar rat which had been immunised against a conjugate 
of 5-HT and bovine serum albumin (Cuello and Milstein 1981). The hybridoma 
secretes specific heavy chains and both specific and non-specific light chains
(Milstein, Wright e t al. 1983). The antibody belongs to  the rat immunoglobulin 
class IgG (Milstein, Wright e t al. 1983).
The antibody specifically recognises the form aldehyde con juga te  of 5-HT. 
Without paraform aldehyde treatm ent, it cross-reacts in liquid phase with 
dopam ine and tryptam ine in haem agglutination tests. It does not react with 
ca techolam ine-conta in ing  neurones in form aldehyde fixed preparations. The 
antibody reacts with 5-HT in neurones and recognises 5-HTergic sites in fixed 
tissue sections (Consolazione, Milstein et al. 1981). The antibody has previously 
been used successfully in anatom ica l studies of the c ircad ian system (Morin and 
Blanchard 1991; Morin, Blanchard et al. 1992; Meyer-Bernstein, Blanchard et al. 
1997; Meyer-Bernstein and Morin 1998).
2.4.2 Source of Tissue
Due to time constraints brought abou t by a change in d irection of the project, 
the analysis of the effects of MDMA on the SCN was taken from animals used in 
a previous study (Colbron, Jones et al. 2002). This looked a t effects of the 
serotonin agonist 8-OH-DPAT and light both pre- and post-MDMA treatm ent. 
There are no known residual effects from this agonist and the MDMA treatments 
used were identica l to those used in the current experiment. All 
im m unohistochem ical procedures were carried out by this author. All animals 
(n=14) were prepared for immunohistochemistry within 4 weeks of the final 
treatm ent as deta iled  below. All tissue for ana tom ica l analysis of the raphe 
cam e from the animals used in the current experim ent (DR, n=12; MR, n=13). 
These were processed for immunohistochemistry, as deta iled  below, between 10 
and 14 days a fte r the final injection of saline.
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2.4.3 Protocol
All animals were deep ly anaesthetised by i.p. in jection of sodium 
pentobarb itone (Dunnwood, Aberdeen, U.K.) and perfused transcardially with 
physiological saline followed by 4% paraform aldehyde in 0.1 M phosphate buffer 
(pH 7.4). Each brain was removed and post-fixed overnight in 4% 
paraform aldehyde before being cryopro tected through a series of sucrose 
solutions in 0.1 M phosphate buffer, ending with 30% sucrose. Brains were then 
frozen and sections of 30 pm were cu t in the coronal p lane and co llected  in 
0.01 M phosphate buffered saline (PBS).
A com bination  of retrograde, anterograde and dual immunofluorescence 
techniques has shown tha t serotonergic innervation of the SCN originates in the 
MR, while tha t of the IGL originates in the DR (Meyer-Bernstein and Morin 1996). 
Injection of retrograde tracers to the SCN showed an equal distribution of 
serotonergic cells throughout the rostrocaudal extent of the MR. A similar 
distribution throughout the DR was found when retrograde tracers were injected 
into the IGL. App lica tion  of anterograde tracers to the MR demonstrates that 
there is a substantial serotonergic fibre plexus concen tra ted  in the medial and 
ventral regions of the SCN. Therefore all sections through the SCN and every third 
section cu t through the aforem entioned areas of the raphe were co llected. A 
stereotaxic atlas of the hamster brain (Morin and W ood 2001) was used as a 
guide to loca te  the relevant stereotaxic coordinates of the brain areas during 
cu tting on the cryostat.
See append ix 1 for a deta iled  protocol of the methods used in this study and 
append ix 2 for the theory behind the chemistry of immunohistochemistry.
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2.5 Anatomical Analysis
2.5.1 SCN
Photomicrographs of stained tissue were obta ined on 400 ASA Kodak cam era 
film using a single lens reflex cam era (K-1000, Pentax) a tta ch e d  to a m icroscope 
(Galen II, Leica). These were digitised using a fla tbed  scanner (Hewlett Packard, 
Scanjet 4470c) to greyscale 75 dpi and im age size of 640x480 pixels. ROD values 
for the SCN were obta ined  using 'Scion Image' software ca lib ra ted  to a 
greyscale density step tab le t (Q-13, Kodak). For each  anim al brain, 4 to 6 
sections were selected from equivalent areas of the SCN using the shape of 
surrounding structures as guide. The optica l density of a control section from 
each brain, which received no primary antibody, was subtracted from the OD 
value of each  section of the same brain. The mean figure for OD of each  brain 
was used in the statistical analysis. See appendix 3 for the theory o f densitometry.
2.5.2 Raphe
Photomicrographs of the raphe were obta ined and digitised as deta iled  above. 
The images were opened in Adobe Photoshop and a grid of 16x8 was used as a 
guide in cell counts. Cell counts were m ade in quadrats from left to right and 
from top  to bottom . Nuclei tha t crossed a grid line were included in the count of 
the first quadra t in which they appeared. Nuclei tha t overlapped and were 
difficult to distinguish as separate cells were counted as one cell.
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2.6 Statistical Analysis
Repeated measures ANOVA were used to analyse phase shifts in activ ity onset 
and activ ity offset, changes in the alpha activ ity period and changes in total 
activity. Changes in t were analysed using t-tests. Differences in ana tom ica l da ta  
betw een MDMA treated animals and untreated animals were ca lcu la ted  using 
a Mann-W hitney U-test. The statistical software used in all cases was G raphpad 
Instat® software.
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3 Results
3.1 Behavioural Analysis
Four animals were excluded from the analysis of phase shift in activ ity onset for 
not m eeting the minimum criteria set. There was a significant d ifference in the 
size of phase shifts in activ ity onset betw een baclo fen and saline before 
treatm ent w ith MDMA (Fig 3.1 & 3.2) but not a fter (F(3,l 1) = 7.865, pO.OOl). There 
was also a significant d ifference between pre-MDMA baclo fen and post-MDMA 
baclofen (Fig 3.2 & 3.3).
For half of the animals, the size of x appeared  to change  afte r baclofen 
injection, which could distort the size of mean phase shifts (Fig 3.4). However 
when analysed, the differences were insignificant both before (Fig 3.5) and after 
(Fig 3.6) MDMA.
Four animals were excluded from the analysis of phase shift in activ ity offset for 
not m eeting the minimum criteria set. Analysis of activ ity offset showed no 
significance betw een any of the drug treatm ent protocols (Fig 3.7). No 
significant differences were found between a lpha activ ity period and total 
activ ity before and a fte r baclofen administration. The d a ta  were pooled for the 
final analysis of MDMA treatm ent but still p roduced non-significant results (Fig 3.8 
& 3.9).
Baclofen had a strong sedative e ffec t on all treated animals on the day of 
injection, which delayed the onset of activ ity by several hours (Fig 3.10). The 
delay betw een the p red icted  onset for the day of injection and  the actua l onset 
was ca lcu la ted  for each  animal. A t-test was used to determ ine whether MDMA
treatm ent changed  the m agnitude of the sedation induced by baclofen. No 
significance was found (Fig 3.11).
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Figure 3.4 Changes in x  subsequent to baclofen treatment.
R e p r e s e n t a t iv e  a c t o g r a m  illu s tra tin g  c h a n g e s  in x a f t e r  
a d m in is t r a t io n  o f  b a c lo f e n .  T h e  g r a d ie n ts  o f  t h e  t w o  lin es  
a p p e a r  d i f fe r e n t ,  a l t h o u g h  th is w a s  f o u n d  n o t  to  b e  s ig n if ic a n t  
w h e n  a n a ly s e d .  T h e  r e d  b lo c k  a r r o w  r e p re s e n ts  t h e  d a y  o f  
d r u g  a d m in is t ra t io n .
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Figure 3.5 Effect of baclofen on x prior to treatm ent with MDMA. T h e re  w a s  
n o  e f f e c t  o f  b a c lo f e n  o n  x w h e n  a n a ly s e d  b y  p a i r e d  t - te s t .
y  Pre-Baclofen t 
□  Post-Baclofen t
Figure 3.6 Effect of baclofen on x subsequent to treatm ent with MDMA. A g a in  
t h e r e  w a s  n o  d i f f e r e n c e  w h e n  a n a ly s e d  b y  p a i r e d  t- te s t .
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Figure 3.10 Actogram  illustrating the sedative effect of baclofen. A n  a c t o g r a m  
i l lu s tra t in g  a  d e la y  in t h e  a c t iv i t y  o n s e t  in a n  a n im a l  t r e a t e d  w ith  b a c lo f e n ,  p r io r  to  
M D M A  a d m in is t r a t io n .  A ll a n im a ls  s h o w e d  th is e f f e c t  s u b s e q u e n t  t o  b a c lo f e n  
t r e a t m e n t .  T h e  g r e e n  lin e  a p p r o x im a t e s  t h e  fo r w a r d  re g re s s io n  lin e  th r o u g h  th e  
a c t iv i t y  o n s e ts  o f  t h e  s e v e n  d a y s  p r io r  t o  d r u g  t r e a t m e n t .  T h e  r e d  b lo c k  a r r o w  
in d ic a te s  t h e  d a y  o f  d r u g  a d m in is t ra t io n . T h e  b lu e  b lo c k  a r r o w  s h o w s  t h e  2 5 6 -m in u te  
d e la y  in a c t iv i t y  o n s e t  s u b s e q u e n t  to  t h e  d r u g  a d m in is t ra t io n .
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3.2 Anatomical analysis
3.2.1 SCN
T h e  o p t ic a l  d e n s ity  in t h e  S C N  o f  a n im a ls  t r e a t e d  w ith  M D M A  (0 .1 1  ±  0 .0 0 5 ;  M e a n  ±  
S E M ) w a s  s ig n if ic a n t ly  r e d u c e d  w h e n  c o m p a r e d  to  u n t r e a t e d  c o n tro ls  ( 0 .5 0  ± 0 .1 6 1 ;  U 
= 4 , P < 0 .0 5 ; F ig u re  3 .1 2  a n d  3 .1 3 ) .
3.2.2 Raphe
N o  s ig n if ic a n t  d i f f e r e n c e  in t h e  n u m b e r s  o f  im m u n o p o s it iv e  c e ll  n u c le i  w a s  fo u n d  
s u b s e q u e n t  t o  t r e a t m e n t  w ith  M D M A  in e ith e r  t h e  d o rs a l (F ig u re s  3 .1 4  a n d  3 .1 6 )  o r  
m e d ia n  (F ig u re s  3 .1 5  a n d  3 .1 7 )  r a p h e  n u c le i.
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
□  Pre-MDMA
□  Post-MDMA
Figure 3.12 O ptical densities of SCN brain tissue stained with antibody against 5-HT.
T h e  d e n s ity  o f  im m u n o h is to lo g ic a l  s ta in in g  fo r  5-FIT w a s  s ig n if ic a n t ly  r e d u c e d  in b ra in s  
t r e a t e d  w ith  M D M A .
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Figure 3.13 Photomicrographs of coronal sections through the SCN stained with 
antibody against 5-HT. A =  C o n tr o l  b r a in . B =  M D M A  t r e a t e d  b r a in . T h e  b i la te r a l  n u c le i  
o f  t h e  S C N  c a n  b e  s e e n  ly in g  a b o v e  t h e  o p t ic  c h ia s m  a n d  b e lo w  t h e  th ird  v e n t r ic le .  
T h e  b r o w n  c o lo u r  is t h e  e n d  re s u lt o f  t h e  im m u n o h is t o c h e m ic a l  s ta in in g  o f  5 -H T  fib re s . 
A  r e d u c t io n  in d e n s ity  c a n  b e  s e e n  in tissue  f r o m  t h e  b r a in  t r e a t e d  w ith  M D M A .  V  =  
th ird  v e n t r ic le ;  O C  =  o p t ic  c h ia s m ; S C N  =  s u p r a c h ia s m a t ic  n u c le u s ; x lO  m a g n if ic a t io n ,  
s c a le  b a r  =  5 0  jam
58
N
um
be
r 
of 
Ce
lls
 
N
um
be
r 
of 
C
el
ls
350 
300 
250 
200 
150 
100 
50 
0
Figure 3.14 Cell counts of 5-HT immunopositive cell bodies within the dorsal raphe  
nucleus. N o  d i f f e r e n c e  w a s  f o u n d  b e t w e e n  c o n tr o l  b ra in s  a n d  M D M A  t r e a t e d  b ra in s .
124 
120 
116 
112 
108 
104 
100
Figure 3.15 Cell counts of 5-HT immunopositive cell bodies within the m edian  raphe 
nucleus. N o  d i f f e r e n c e  w a s  f o u n d  b e t w e e n  c o n tr o l  b ra in s  a n d  M D M A  t r e a t e d  b ra in s .
Pre-MDMA
Post-MDMA
Pre-MDMA
Post-MDMA
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Figure 3.16 Photomicrographs of coronal sections through the dorsal raphe nucleus 
stained with antibody against 5-HT. A  =  c o n tr o l  b ra in . B =  M D M A  t r e a t e d  b r a in . x lO  
m a g n i f ic a t io n ,  s c a le  b a r  =  5 0  f im .
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4 Discussion
4.1 Phase Shifting Effect of Baclofen at CT6
Systemic administration of 10 m g/kg of R(+)-baclofen hydrochloride to Syrian 
hamsters a t CT6 results in a phase advance  shift in the onset of activ ity rhythms 
tha t is significantly d ifferent from the phase shift induced by control injections of 
saline adm inistered a t the same time. The phase and d irection of these baclofen 
shifts are similar to those of shifts induced by other non-photic stimuli, indicating 
that GABAb receptors m ay be involved, either d irectly or indirectly in the 
m ediation of phase shifts of this type.
This result is in agreem ent with previous work dem onstrating baclofen-induced 
phase advance  shifts of SCN neuronal activ ity in vitro  a t ZT6 (Biggs and Prosser
1998) and of activ ity  rhythms in vivo  a t CT6 (Smith, Turek et al. 1990). The phase 
shifts from the in vivo  study were of a similar m agnitude to those observed here 
despite the fa c t tha t the lighting conditions were different (LL as opposed to 
DD). The phase advances in vitro were larger (97.8 ± 24 minutes) than those 
resulting from this study (43.4 ± 9.8 minutes). The differences seen betw een these 
two types of study m ay be due to the loss off inhibitory a fferent input to the 
pacem aker in the SCN slice preparation resulting in a greater m agnitude of 
phase shift.
An a lternative explanation for the d ifference in the m agnitude of phase 
advances m ay be due to  the sedative e ffec t of baclofen. On the days when 
baclo fen was used as the phase shifting stimulus, there was a m ean delay in the 
onset of activ ity  of 207.8 ± 37.3 minutes. There was no d ifference subsequent to 
MDMA administration (279.6 ± 31.8 minutes), which would ind icate  that the
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mechanism for this e ffec t does not involve 5-HT. It has been previously shown 
tha t restriction of activ ity can a c t as a phase shifting stimulus in itself (Van Reeth, 
Hinch et al. 1991). It was found tha t under LL conditions, a three-hour period of 
immobilisation a t CT12 resulted in a phase delay of 51 ± 9  minutes. Since 
baclo fen administration appeared  to restrict all activ ity onsets by similar period, 
it m ay be tha t phase advances to baclofen a t CT6 m ight have been larger but 
have been coun terba lanced  by a phase delay from immobilisation due to the 
drug. It m ay also have been tha t the animals were still active  subsequent to drug 
administration but unable to engage in wheel-running activity. This could have 
been clarified through the use of infrared m ovem ent detectors p laced  around 
the animals’ cages.
4.2 The SCN as the Site of Action for Baclofen
Systemically administered baclofen has the potentia l to induce phase advances 
by ac ting  a t any site within the circad ian system where GABAb receptors are 
loca ted . GABAb receptors are known to be present within the SCN both from 
studies utilising in situ hybridisation (Lu, Ghasemzadeh et al. 1999) and 
immunohistochemistry (Margeta-M itrovic, Mitrovic e t al. 1999). The in situ 
hybridisation study would ind icate  tha t GABAb receptors are expressed by SCN 
cells and a direct, postsynaptic e ffec t of baclofen has previously been shown. 
One in vitro study (Jiang, Allen et al. 1995) found tha t bac lo fen  caused an 
outward current in SCN cells tha t was not b locked by TTX. Since TTX prevents the 
propagation  of sodium -dependant action potentials this would ind ica te  tha t the 
baclo fen was acting  directly on pacemakers cells. The outward current 
p roduced was associated with an increase in m em brane conductance  
consistent with an increase in potassium co nduc tance  and resulted in inhibition 
of SCN cells. An in vivo  study investigating photic signalling a t CT13.5 also found
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evidence for a d irect e ffec t of baclofen on SCN cells (Mintz, Jasnow et al. 2002). 
It was found tha t phase shifts to m icroinjection of a g lu tam ate  agonist were 
significantly reduced by baclofen and tha t this reduction was also unaffected 
by TTX. It m ay be tha t the phase advances observed in this study, a t CT6 a time 
when the e lectrical activity of SCN cells is high, are brought abou t by 
postsynaptic inhibition by baclofen. The mechanism for this could be 
hyperpolarisation and so a reduction in the e lectrica l activ ity of SCN cells 
resulting from the opening of inwardly rectifying potassium channels.
It is also thought tha t baclo fen can have a presynaptic e ffec t in the SCN. The 
phase advances in spontaneous electrical activ ity induced by baclo fen a t ZT6 in 
vitro  were b locked by TTX suggesting a presynaptic action  (Bergeron, Danielson 
et al. 1999). Application of baclofen in vitro can inhibit the release of g lu tam ate  
through activa tion  of GABAb heteroreceptors on terminals of the 
re tinohypothalam ic trac t (Jiang, Allen et al. 1995). It m ay be that baclofen 
phase advances are induced by disinhibition of inhibitory afferents to the SCN. 
GABAb receptors m ay be present on afferents from the GHT. The e ffec t of 
baclofen on these receptors would be to inhibit the release of GABA and /o r NPY 
and so rem ove the inhibitory e ffect of these neurotransmitters on cells of the 
SCN. This mechanism seems unlikely however, since coexpression of GABAbi 
receptors and GAD was not found by immunohistochemistry (Margeta-M itrovic, 
M itrovic et al. 1999). Evidence from cultured SCN neurones indicates tha t 
activation of GABAb receptors by baclofen results in a strong presynaptic 
inhibition of GABA release from these cells (Chen and van den Pol 1998). Thus it 
m ay be tha t baclo fen activates autoreceptors on GABAergic interneurones 
within the SCN resulting in the reduction of neurotransmitter release and 
ultimately in a phase advance.
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Thus baclo fen m ay result in phase advances of hamster activ ity rhythms by 
acting  a t the level of the SCN. This m ay be either by d irect inhibition of SCN cells 
or by a reduction in transmitter release from afferent pathways or possibly a 
com bination  of both. Since in situ hybridisation and im m unohistochem ical 
studies have found evidence for the presence of GABAb receptors throughout 
the c ircad ian system, it seems likely tha t baclofen could a c t a t any of these sites. 
It may be tha t the observed phase shift a t CT6 is the net result of stimulation of 
GABAb receptors a t both pre- and postsynaptic sites.
4.3 The Raphe Nuclei as the Site of Action for Baclofen
Both in situ hybridisation (Lu, Ghasemzadeh et al. 1999) and
im m unohistochem ical techniques (Margeta-M itrovic, M itrovic et al. 1999) have 
ind ica ted  tha t GABAb receptors are also present within the raphe. Com bined 
immunohistological staining for both 5-HT and GABAb receptors indicates tha t all 
serotonergic cells in both raphe nuclei express GABAbi recep to r subunits (Varga, 
Sik et al. 2002). This study found a t both light and electron m icroscope level that 
the subcellular location of GABAb receptors was on proximal dendrites and cell 
bodies. This would ind icate  tha t systemically administered baclo fen could a c t on 
these GABAb receptors to inhibit the firing of raphe cells causing reduction of 
both 5-HT metabolism and its release in projection areas. The 5-HTergic cells of 
the MR pro ject to the SCN while those of the DR pro ject to the IGL. 
Administration of baclo fen a t CT6 could result in changes in 5-HT levels in these 
areas and so lead to a phase shift.
The effects of GABAb recepto r stimulation by baclofen has been studied in both 
raphe nuclei by a com bination of microdialysis and  electrophysiological
techniques (Tao, Ma et al. 1996; Abelian, Adell e t al. 2000; Abelian, Jolas et al.
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2000). From these studies, it would appear tha t the net e ffe c t o f systemically 
adm inistered baclo fen on 5-HT neurones in the raphe results from a balance 
betw een d irect postsynaptic inhibition and indirect presynaptic disinhibition. 
Lower doses of baclo fen were found to have a preferential action at 
presynaptic GABAb recepto r sites while the GABAb antagonist phaclo fen cannot 
fully b lock the effects of higher doses of baclo fen (Abelian, Jolas e t al. 2000). 
These observations would suggest the presence a t the d ifferent cellular 
locations, of a lternate GABAb receptor subtypes with varying affinities for agonist 
and antagonist.
The dose of drug used in these experiments was 10 m g/kg of baclofen 
hydrochloride. A dose response curve for R(+)baclofen has been previously 
reported (Ralph and M enaker 1989). The maximal inhibition of phase shifts to 
light by R(+)baclofen is achieved a t a dose of 15 m g/kg. The baclofen 
hydrochloride used in these experiments is a more water-soluble version of 
baclofen and has been shown to produce a significant reduction in light- 
induced c-fos production in cells of the SCN a t 10 m g/kg (Crosio, Cermakian et 
al. 2000). Thus systemic administration of baclofen a t the lower dose used of 10 
m g/kg m ay a c t preferentially a t presynaptic GABAb autoreceptors on inhibitory 
GABAergic neurones tha t synapse on raphe 5-HT neurones. GABAergic input to 
the raphe is high during the day (Nitz and Siegel 1997), so baclo fen would 
reduce the GABAergic inhibition on 5-HT neurones resulting in an increase of 
serotonin metabolism and release. This would be in agreem ent w ith the in vitro 
work which dem onstrated an increase in the release of newly synthesised 5-HT in 
the SCN subsequent to baclofen administration during the subjective day 
(Francois-Bellan, Hery e t al. 1987). This increase in serotonin release from the MR- 
SCN pa thw ay m ay be involved in the phase advances observed.
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If low doses of baclo fen  show preferential action at presynaptic GABAb 
receptors, then the MR serotonergic terminal zone in the SCN m ay be another 
site of drug action. Stimulation of GABAb autoreceptors on these afferents would 
result in a reduction in 5-HT release and disinhibition of SCN cells possibly leading 
to a phase shift. MDMA was administered by i.p. in jection in increasing doses 
over three consecutive days. This is a protocol known to  be neurotoxic to 
serotonergic neurones resulting in degeneration of term inal areas in rodents 
(O'Hearn, Battaglia et al. 1988). This can be seen in our study as a significant 
reduction in the optica l density of the serotonergic term inal field within the SCN. 
If 5-HT is involved in m ediation of baclofen phase advances, then it would be 
expected  tha t a reduction of the terminal 5-HT field would a ffe c t the 5-HT being 
released within the SCN and so a ffec t the size of the baclo fen-induced phase 
advances. The phase advances to baclofen subsequent to MDMA lesions were 
indeed significantly smaller. Thus it seems likely tha t a presynaptic action of 
baclo fen on 5-HTergic cells from the MR that synapse on the SCN may be 
involved in phase shifts to this agent a t CT6.
It may be possible tha t the phase shifts to baclo fen a t CT6 are m ediated by the 
5-HTergic innervation of the IGL. The IGL is known to be involved in the mediation 
of non-photic phase shifts a t CT6 through release of NPY (Biello, Janik e t al. 1994) 
and /o r GABA (Morin and Blanchard 2001) onto the SCN. If GABAb receptors are 
present on the 5-HTergic pa thw ay from the DR to  the IGL, then these may also 
be involved in m ediation of non-photic phase shifting. Activation of these 
receptors would result in a reduction in 5-HT released onto the IGL. This would 
remove an inhibitory influence on the IGL and so result in an increase in the 
am ount o f NPY a nd /o r GABA released onto the SCN from the GHT tha t may lead 
to a phase shift.
There also appears to be differences in the e ffec t of baclo fen  a t different times 
of day. Local administration of baclofen through microdialysis probes to the DR 
during the lights-off period results in a reduction in extracellular 5-HT both in the 
DR and a projection area (Tao, Ma et al. 1996). However, local administration in 
the DR (Abelian, Jolas e t al. 2000) or MR (Abelian, Adell e t al. 2000) during the 
lights-on period results in an increase in extracellular 5-HT. It is known from in vivo  
microdialysis experiments tha t extracellular 5-HT levels in the SCN area are at 
their lowest a t CT6 under DD conditions (Dudley, DiNardo et al. 1998). Thus it may 
be tha t systemically administered baclofen a t this time increases the release of 
5-HT which ultimately leads to a phase advance  shift of the activ ity rhythms.
Some authors have specula ted tha t there is a reciprocal 5-HTergic pathw ay 
betw een the DR and MR. Electrical stimulation of either the MR or DR a t CT6 both 
resulted in significant phase shifts in activity rhythms (Meyer-Bernstein and Morin 
1999). Microdialysis measurement has shown tha t e lectrical stimulation of the DR 
produces an equivalent release of 5-HT within the SCN area as tha t p roduced by 
stimulation of the MR (Dudley, Dinardo et al. 1999). Systemic administration of the 
non-specific 5-HT antagonist metergoline b locked the release of 5-HT subsequent 
to DR stimulation but had no e ffec t on the release subsequent to MR stimulation 
(Dudley, Dinardo et al. 1999). M icroinjection of the 5-HTia au to recep to r agonist 8- 
OH-DPAT or the antagonist WAY 100635 directly to the MR resulted in inhibition 
and stimulation respectively of 5-HT release within the SCN. Similar microinjections 
to the DR had no e ffec t on 5-HT release within the SCN (Dudley, Dinardo et al.
1999). GABAb receptors, if present on this pathw ay would be an additional 
substrate through which phase shifts to baclofen m ay be m ediated.
Thus there are a num ber of possible sites for the actions of systemically 
adm inistered baclo fen on the raphe nuclei during the subjective day. The drug
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may be acting  presynaptically to inhibit neurotransmitter release onto cells of 
either nucleus. The action  may be directly on receptors of raphe cells and so 
inhibit cell firing and metabolism. Alternatively, GABAb heteroreceptors on 
terminals of the MR to SCN pathw ay may be a ffecting  transmitter release in this 
nucleus. It m ay be a com bination of all of these, however the strongest possibility 
from the current d a ta  would be the last of these. MDMA caused a measurable 
decrease in 5-HTergic innervation of the SCN and this was paralleled by an 
a ttenuation of phase shifts to baclofen.
4.4 The Effect of Baclofen on the Molecular Clock
It has previously been shown tha t several different non-photic stimuli a c t both to 
produce phase advances in activity rhythms and to reduce production of PER 
within the SCN during the subjective day. These stimuli include novel wheel 
running (M aywood, Mrosovsky et al. 1999), injection of NPY (M aywood, Okamura 
et al. 2002), in jection of 8-OH-DPAT (Horikawa, Yokota e t al. 2000) or injection of 
benzodiazepines (Yokota, Horikawa et al. 2000). It m ay be tha t the phase 
advances p roduced by baclofen in these experiments are also as a result of the 
reduction in Per expression within the SCN. Expression of Per during the day is 
maximal (M aywood and Mrosovsky 2001) and a reduction in this through 
baclofen administration would ultimately change the pattern of clock gene 
expression within the SCN. This in turn would lead to changes in the expression of 
c lock-controlled genes involved in output pathways such as TGFa, a molecule 
tha t has been im plicated in the control of hamster activ ity  rhythms (Kramer, 
Yang et al. 2001).
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4.5 The Neurotoxic Effect of MDMA
Dam age to the 5-HTergic system through the use of neurotoxins other than 
MDMA has been previously shown to a ffec t various param eters of circadian 
rhythmicity. The neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) can destroy 5- 
HTergic terminals, fibres and neurones w ithout dam ag ing  other neurotransmitter 
systems. Lesions induced through the use of this neurotoxin have been shown to 
have effects on several c ircad ian rhythm parameters. Under the entraining 
conditions of a light-dark cycle, activ ity onset usually occurs just a fte r lights-off for 
nocturnal rodents. Subsequent to lesioning by 5,7-DHT however, activity onset 
occurs slightly before lights-off and activ ity offset is usually de layed by 1.5 to 2 
hours, a lthough the tota l activ ity for the period remains the same (Morin 1999). In 
hamsters under constant darkness, c ircad ian rhythm icity persists w ithout any 
alteration in period, a lthough the expanded activ ity phase persists (Morin and 
Blanchard 1991). This differs from the effects tha t were observed in this study 
where lesioning by MDMA had no e ffec t on either the a lpha activ ity phase or 
tota l activity. This m ay be due to differing sites of action of the tw o neurotoxins. 
The e ffec t of 5,7-DHT on activ ity onset, offset, a lpha period and tota l activity is 
similar w hether the lesions are intraventricular or induced by injection directly to 
the MR (Morin 1999). It is possible tha t the effects of 5,7-DHT occur through the 
destruction of 5-HTergic cell bodies within the MR since the effects of this 
neurotoxin can occur by retrograde degeneration of nerve cells (Morin and 
Blanchard 1991; Morin 1992). MDMA however is known to  result in the depletion 
of 5-HTergic axons and axon terminals with very little e ffec t on cell bodies (Stone, 
Stahl e t al. 1986) as confirm ed by the results of this study. A d ifference between 
the effects of MDMA and 5,7-DHT has previously been shown with respect to 
c ircad ian rhythm icity (Colbron, Jones et al. 2002). This study found tha t phase 
shifts to light were a ttenua ted  subsequent to MDMA treatm ent, an e ffect
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opposite to the e ffec t of 5,7-DHT tha t results in augm enta tion  of phase shifts to 
light (Morin and Blanchard 1991).
An alternative explanation for the d ifference betw een the effects on activity of 
these two neurotoxins m ay be provided by a study tha t com pared  the e ffect of 
in jecting 5,7-DHT directly into the MR with the e ffec t o f injections d irectly to the 
SCN (Meyer-Bernstein, Blanchard et al. 1997). It was found tha t bilateral infusion 
of 5,7-DHT into the SCN area resulted in d ifferent behavioural circadian 
parameters under a LD cycle  than when the neurotoxin was diffused directly into 
the MR, even though both methods virtually e lim inated 5-HTergic innervation of 
the SCN. Infusion to the MR, and so destruction of cell bodies, resulted in the 
usual a dvance  in the onset of activity, delay in offset and extended activity 
phase. However bilateral infusion to the SCN, and so presumably destruction of 
terminal areas, resulted in earlier activ ity onset but had no e ffec t on either offset 
or duration of the activ ity phase. The interpretation of this d a ta  a t the time was 
tha t the 5-HTergic pa thw ay from the MR to the SCN contro lled the onset of 
activ ity but not any of the other circad ian parameters. It was suggested tha t 5- 
HTergic innervation from the MR to other brain areas indirectly controlled the 
other param eters through alternate transmitter systems. A comparison can be 
drawn from this with the present study. MDMA caused a reduction in 5-HTergic 
cell terminal areas with no e ffec t on cell bodies within the MR, a situation similar 
to bilateral infusion of 5,7-DHT into the SCN. MDMA had no e ffe c t on alpha 
period or to ta l activity, it d id however cause a change  in the tim ing of activity 
onset.
The m ode of administration of the neurotoxins m ay also contribute to the 
observed differences in e ffect. Experiments involving 5,7-DHT utilise local injection 
of the neurotoxin a t specific stereotaxic coordinates. This results in lesions of
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specific ta rge t pathways, which allows the contribution of tha t particular 
pa thw ay in phase shifting to be assessed by subsequent experiments. MDMA is 
however adm inistered systemically which results in g lobal neurotoxicity of 5- 
HTergic pathways. O ther areas of the brain tha t are rich in 5-HT m ay a c t on input 
pathways to  the c ircad ian system. Dam age to the fibres caused by MDMA in 
these areas will also contribute to changes in the functioning of the circadian 
system.
The neurotoxic effects of MDMA would also be expected  in the 5-HTergic 
terminal field within the IGL. It has been shown tha t MDMA has a greater 
neurotoxic e ffec t on neurones originating from the DR than those originating 
from the MR, possibly due to the anatom ica l differences in the 5-HTergic 
innervation originating from these two nuclei (O'Hearn, Battaglia e t al. 1988). 
Neurons from the MR are predom inantly of a 'beaded ' variety characterised by 
numerous rounded varicosities 2 to 3 pm in d iam eter while those of the DR are of 
a more uniform thin calibre type (Kosofsky and Molliver 1987). However, in the 
hamster there is no m orphological d ifference betw een 5-HTergic innervation of 
the IGL or SCN with afferents to both areas being very fine with small fusiform 
terminals (Morin and Meyer-Bernstein 1999). Since dam age  was found to MR 
terminals in the SCN and tha t DR terminals are generally more susceptible to 
neurotoxic dam age  from MDMA, it seems probable  tha t there would be 
dam age  to the 5-HTergic innervation of the IGL. Thus it may be tha t dam age to 
5-HTergic terminals in the IGL may be responsible for, or contribute to, the 
a ttenuation of baclo fen induced phase shifts observed subsequent to MDMA 
administration.
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4.6 Future Directions
One of the major shortcomings of the experiments used in this study is the 
inability to  distinguish the exact site of action of systemically adm inistered 
baclo fen within the c ircad ian system. One techn ique com m only used in 
c ircad ian research which overcomes this is the use of indwelling guide cannulae 
im planted with the use of stereotaxic positioners. These can be a im ed d irectly a t 
specific areas of the brain from known stereotaxic coordinates and a llow  direct 
app lica tion  of drugs to an area of interest such as the SCN or the raphe nuclei. 
This techn ique has previously been used successfully to investigate the e ffec t of 
baclofen within the SCN. One study looked at the effects o f bac lo fen  on light 
induced delays and advances during the night (Gillespie, Mintz e t al. 1997) while 
another looked a t the d irect e ffect of baclofen on the SCN a t CT6 under 
constant light (Smith, Turek et al. 1990). No experiments have been carried out 
using this techn ique a t CT6 under conditions of constant darkness. No study so 
far has looked a t the effects of baclofen in jected through cannu lae aim ed 
directly a t either of the raphe nuclei or the IGL.
The involvem ent of 5-HT in systemically administered baclo fen  phase advances 
could be further exam ined by com bination with local in jection of antagonists of 
5-HT receptors. There are several different 5-HT receptors tha t are known to be 
present within the c ircad ian system. Selective antagonists are availab le  for 
several of these enabling the b lockade of tha t particular receptor. Used in 
com bination  with systemically administered baclo fen would a llow  clearer 
identification of the neural pa thw ay along which baclo fen mediates its effects.
Recent ev idence suggests tha t GABAb receptors are com posed of different 
recepto r subtypes and tha t different combinations of these vary in their
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pharm aco log ica l properties. It has also been suggested tha t the different 
subtypes are coup led  to alternate signal transduction mechanisms such as G 
proteins. It has been previously shown in vitro tha t pertussis toxin can discriminate 
betw een pre- and postsynaptic actions of baclofen in the rat DR (Colmers and 
Williams 1988). If a similar treatm ent was to be used in vivo, then it may be 
possible to determ ine the contribution of the d ifferent subtypes to baclofen 
phase shifts a t CT6 and allow a closer determ ination of the exact location of 
these receptors.
The neurotoxic e ffec t of MDMA on the 5-HTergic terminal field within the SCN 
was exam ined in this study. No accoun t was taken of any similar toxicity to the 5- 
HTergic term inal field within the IGL. A similar im m unohistochem ical examination 
of any dam age  to this area would be necessary before any firm conclusion 
could be drawn regarding the exact location of the site of action  of systemically 
administered baclofen.
4.7 Conclusions
Systemic administration of the GABAb agonist baclofen during the subjective day 
to Syrian hamsters, results in a significant phase advance  shift of activ ity rhythms 
when com pared  to control injections of saline adm inistered a t the same time. 
This would ind ica te  tha t GABAb receptors m ay have a role in the m ediation of 
non-photic phase shifting of the circad ian clock since this is a time a t which 
other non-photic stimuli p roduce phase advances. This has implications for the 
treatm ent of c ircad ian rhythm disorders in tha t drugs tha t a ffect 
neurotransmission through the GABAb receptor m ay have potentia l therapeutic 
value.
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(Further, neurotoxic dam age  to the 5-HTergic innervation of the SCN induced by 
the substituted am phetam ine MDMA resulted in a ttenuation  o f the phase shifts 
induced by baclo fen. This suggests tha t the 5-HTergic innervation of the SCN is 
involved in baclo fen-induced phase advances. It has previously been shown 
tha t MDMA reduces tha t ability of the SCN to phase shift to  a different non- 
photic stimulus as well as to light (Colbron, Jones et al. 2002). It is known that 
there is an increase in the use of MDMA as a recreational drug tha t may lead in 
the future to increasing incidences of c ircad ian rhythm disorders.
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Appendix 1: Immunohistochemistry Protocol 
A1.1 Chemicals Used and Sources
Chemical Name
5HT antibody; clone YC5/45
Biotinylated anti-rat IgG m ade in rabbit 
DPX m ountant 
DAB substrate kit
Hydrochloric ac id
Hydrogen peroxide 
Normal rabb it serum
Paraform aldehyde
Potassium chloride 
Sodium b ica rbonate  
Sodium chloride 
Sodium hydroxide
Sodium phosphate dibasic anhydrous 
Sodium phosphate m onobasic dihydrate
Sucrose 
Triton® X-100
Vectastain ABC Kit - Standard peroxidase 
Xylene
Supplier Code Supplier Address
YMC1019
A ccura te  Chem ical & 
Scientific Corporation,
BA-4000
Westbury, NY, USA 
Vector, Peterborough, UK
44581 Sigma-Aldrich, Poole, UK
SK-4100 Vector, Peterborough, UK
H / l150/PB17 Fisher Scientific, Loughborough, UK
285196H BDH, Poole, UK
S-5000 Vector, Peterborough, UK
16965-0010 Fisher Scientific, Loughborough, UK
P5405 Sigma-Aldrich, Poole, UK
S5761 Sigma-Aldrich, Poole, UK
S5886 Sigma-Aldrich, Poole, UK
930-65 Sigma-Aldrich, Poole, UK
S5136 Sigma-Aldrich, Poole, UK
71509 Sigma-Aldrich, Poole, UK
S/8560/63 Fisher Scientific, Loughborough, UK
BPE151-100 
PK-4000
Fisher Scientific, 
Loughborough, UK
Vector, Peterborough, UK
X/2022/17 Fisher Scientific, Loughborough, UK
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A1.2 Stock Solutions
0.2M Phosphate Buffer Solution (PB):
A sodium phosphate monobasic d ihydrate 6.24 g in 200 ml double  distilled w ater
(ddbhO)
B sodium phosphate dibasic anhydrous 28.4 g in 1000 ml ddhteO
>  mix 190 ml of A with 810 ml of B
>  check the pH is -7.4, if necessary adjust with 1M sodium hydroxide or 1M
hydrochloric ac id
Perfusion Buffer:
per litre: distilled w ater (ddH20) 950 ml
0.2M buffer stock solution 50 ml
sodium chloride (NaCI) 8.25 g
potassium chloride (KCI) 0.25 g
sodium b icarbonate  (NaHCCb) 0.5 g
4% Paraformaldehyde (PAM):
per litre: ddH20 500 ml
0.2M buffer stock solution 500 ml
NaCI 8.8 g
KCI 0.2 g
paraform aldehyde 40 g
> hea t solution to 60°C on a stirring hotp la te
> stir until solution clears then filter through a double layer of filter paper
Sucrose solutions:
per 100 ml 10% lOg of sucrose in 0.2M PB
20% 20g of sucrose in 0.2M PB
30% 30g of sucrose in 0.2M PB
0.01 M Phosphate Buffered Saline (PBS):
per litre: ddH20 950 ml
0.2M buffer stock solution 50 ml
NaCI 8.8 g
KCI 0.2 g
0.01 M phosphate buffered saline with Triton-X (PBS+T):
per litre: PBS 997 ml
Triton-X 3 ml
1% Hydrogen Peroxide Solution:
per 30 ml: PBS+T 29 ml
30% hydrogen peroxide (H2O2) 1 ml
Blocking Solution:
per 10 ml: PBS+T 9.7 ml
normal rabbit serum (3%) 300 |jl
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Primary Antibody (1:100):
per 10 ml: blocking solution 9.9 ml
antibody -  YC5/45 100 |jl
Secondary antibody (1:200):
per 10 ml: PBS+T 9.95 ml
biotinylated rabbit anti-rat 50 |jl
Avidin-biotin complex (ABC):
per 5 ml: PBS+T 5 ml
reagent A 1 drop
reagent B 1 drop
> make up a minimum of 30 minutes before use
Diaminobenzidine solution:
per 5 ml: ddhteO
buffer solution 
DAB solution 
H2O2
A1.3 Procedure
1. Wash:
a. using a transfer p ipette  to remove the PBS solution in which the 
sections were co llected  and rep lace with fresh PBS solution
b. p lace  culture plates on the rotary shaker to ag ita te
c. a llow to wash for 10 minutes
d. repea t this process for a second 10 minute wash
2. Quenching endogenous peroxidase activity:
a. remove the wash solution
b. rep lace with 1 % H2O2 in PBS+T and ag ita te  for 5 min
3. Wash:
a. 2 x 10 minutes in PBS -  as above
4. Blocking non-specific background staining:
a. rem ove the wash solution
b. app ly  b locking solution
c. incuba te  tissue in blocking solution with agita tion for 1.5 hours at 
room tem perature
5. Primary antibody:
a. keep one section as a non-specific staining control and remove 
blocking solution from all o ther sections
b. app ly  primary antibody
c. secure lids onto  plates with sellotape
d. incuba te  for 3 days a t 4°C
6. Wash:
5 ml 
2 drops 
4 drops 
2 drops
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a. using a transfer p ipette  to remove the primary antibody and replace 
with PBS
b. p lace  culture plates on the rotary shaker to ag ita te
c. a llow to wash for 10 minutes
d. repeat this process for a second 10 minute wash
7. Secondary antibody:
a. remove the wash solution
b. app ly  secondary antibody using a 1 ml Gilsen p ipe tte
c. incubate  for 90 minutes with agitation a t room tem perature
6. Wash:
a. 2 x 10 minutes in PBS -  as above
7. ABC solution:
a. rem ove the wash solution
b. app ly  ABC solution using a transfer p ipette
c. incubate  for 90 minutes with agitation a t room tem perature
8. Wash:
a. 2 x 1 0  minutes in PBS -  as above
9. DAB visualisation:
a. app ly DAB solution with a transfer p ipette  and allow 2 to 5 minutes 
incubation until a suitable intensity of staining is ach ieved
b. carry out this stage on one culture dish a t a time to prevent over­
staining
10. Wash:
a. 2 x 1 0  minutes in PBS -  as above
11. Specimen mounting:
a. dehydra te  through increasing concentrations of a lcohol
b. c lear in xylene
c. coverslip and m ount with DPX m ountant
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Appendix 2: Immunohistochemical Theory
A2.1 Antibodies
Antibodies are a class of proteins, the immunoglobulins, p roduced by B- 
lymphocytes of the immune systems of animals in response to invasion of the 
body by foreign molecules. They form one or more Y-shaped units, which are 
each com posed of four po lypeptide  chains. Each of these Y-shaped units 
contains tw o identica l copies of a 'heavy' chain and tw o identica l copies of a 
'light' chain, nam ed based on their relative m olecular weights. There are five 
classes of an tibody based on the number of Y-units and the type of heavy chain 
(IgG, IgM, IgA, IgD and IgE). Antibodies are p roduced by the immune system in 
response to  antigens, which are high m olecular w e ight chem icals such as 
proteins or polysaccharides. Smaller substances known as haptens, if these are 
chem ically coup led to a larger carrier protein such as bovine serum albumin 
may also genera te  immune responses.
Antibodies bind to antigens a t a specific site known as an ep itope. This is usually 
one to six m onosaccharide or am ino ac id  residues on the surface of the antigen. 
Conform ational epitopes are dependant upon a specific three-dimensional 
antigenic conform ation such as would be form ed from the interaction of two 
native protein subunits. Linear epitopes correspond to a simple primary 
sequence. The range of possible binding sites for antibodies is large with each 
having its own structural properties depend ing upon the type of molecular 
bonding present. The bonding between antibody and antigen is dependant 
upon non-cova lent bonding such as hydrogen bonds, hydrophobic bonds, 
e lectrostatic forces and van der Waals forces. Im m unochem ical techniques rely 
upon the specific binding properties of an antibody for its antigen.
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IAntibodies are p roduced for use in im m unochem ical research by repeatedly 
immunising a suitable animal by a suspension of the antigen of interest. Blood 
serum is harvested a t the peak of antibody production and  the antibodies 
isolated. When very large antigen molecules are used for the immunisation, the 
resulting antibodies are said to be polyclonal. This is due to the large number of 
epitopes on the surface of the antigen molecule, each  of w hich results in the 
production of an immunoglobulin specific for tha t epitope. Polyclonal antibodies 
have the d isadvantage tha t they can cross-react with other epitopes on the 
antigen m olecule. M onoclonal antibodies are hom ogenous populations of 
immunoglobulins p roduced  by hybridomas, which are the result of the fusion of a 
B-lymphocyte with an immortal cell line. These antibodies all recognise the same 
ep itope but because of this are sensitive to changes it the ep itope  brought 
about by processes such as chem ical fixation of tissue samples. M onoclonal 
antibodies are used as the primary antibody in im m unochem ical research due 
to their high specificity and results can be highly reproducib le  if experimental 
conditions are kept constant.
The de tec tion  of antigens in b io logical tissue is known as immunohistochemistry 
(IHC). In this technique, an antibody is used to link a cellular antigen to a stain 
tha t can be observed under the m icroscope. There are three main stages 
involved in IHC, specimen preparation, antibody staining and antibody 
detection .
A2.2 Specimen Preparation
The cells and tissues have firstly to be preserved in a life-like manner. This is 
ach ieved by the use of fixatives, which are chemicals tha t stabilise the cells and
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tissues and p ro tec t them  from the rigors of processing and staining techniques. 
Tissues have differing protein content and so differing abilities to retain their 
structure depend ing  upon fixation m ethod used. The methods tha t are best for 
the preservation of tissue structure generally work by altering proteins, which may 
result in the masking of some epitopes and so b lock or im pede antigen labelling. 
Fixatives m ay work by form ation of cross-linkages betw een reactive groups in the 
po lypeptide  chains of proteins or by protein denaturation by coagula tion, or a 
com bination of the two. Requirements for fixation varies w idely betw een tissue 
types, so methods used must be optim ised for each  in order to retain antigens 
and cellular structure while keeping ep itope masking to a minimum.
Perfusion fixation involves the pum ping of fixative through the vascular system of 
an in tac t animal. The animal is given an injection of anaesthetic and has its 
chest cavity  opened. A needle connected  to a supply of physiological saline is 
inserted into the left ventricle of the heart and the right atrium is cut. The saline is 
a llowed to flow a t a steady pressure and so pumps out all the b lood from the 
body. The saline is then rep laced  by fixative and this is a llowed to  flow at a 
steady pressure through the body. The tissue of interest is then harvested. This 
m ethod has the advan tage  of being quick as well as allow ing the fixative good 
accessibility to all tissues throughout the body.
There are several methods of preparing sections of tissue sample for use in IHC. 
Cryostat sectioning involves the rapid freezing o f the tissue sample for cutting on 
a cryostat. This m ethod allows good antigen preservation and  the use of many 
different fixatives so allow ing optim isation of fixative for each  antigen. The 
sections p roduced by this m ethod can be stained free-floating and not slide 
m ounted which allows greater surface area for incubation. This m ethod however 
gives less m orpholog ica l deta il and resolution.
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A2.3 Antibody Staining
The purpose of immunohistochemistry is to identify the presence or absence of a 
particular antigen within a tissue sample. There are several methods of achieving 
this but all involve exposing the tissue to an antibody raised against the molecule 
of interest. Detection of the antibody is ach ieved through several stages that 
ultimately result in a ttachm ent of a label tha t can be viewed under the 
m icroscope. The primary antibody may be directly labelled, or unlabelled, with 
de tection  ach ieved  by a labelled secondary antibody. If a secondary antibody 
is used, it must be genera ted against the immunoglobulin of the anim al in which 
the primary antibody was raised. For instance, if the primary an tibody was raised 
in rat then the secondary antibody could be raised in rabbit against rat 
immunoglobulin. Antibodies bound in tissue samples can be d e te c te d  by several 
methods. Enzyme-mediated detection  involves the use of enzymes such as 
horseradish peroxidase or alkaline phosphatase as the label. These are then 
reacted  with a suitable substrate tha t yields a precip ita te . Various signal 
am plification techniques can be used to increase the signal to antibody ratio 
and so allow bette r visualisation of the end product.
A2.4 Avidin-Biotin Technique for Antibody Detection
Avidin is a g lycoprote in tha t has such high affinity for the small vitamin biotin that 
reaction betw een the tw o molecules is essentially irreversible. Each m olecule of 
avidin has four binding sites for biotin. Additionally, a variety of biological 
molecules including antibodies and enzymes can be con juga ted  to several 
molecules of biotin. Following from this, biotinylated proteins can  each  a ttach  to 
more than one m olecule of avidin. These properties have been exploited in
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im m unohistochem ical techniques to allow the formation o f m acrom olecular 
complexes betw een avidin and biotinylated proteins. The ABC technique 
employs unlabeled primary antibody, followed by b io tinylated secondary 
antibody and  then a preform ed avidin and b iotinylated horseradish peroxidase 
m acrom olecular com plex (ABC). The biotin molecules on the secondary 
antibody react with the ABC and as a result greatly am plify the antibody signal 
(Figure A2.1).
An enzyme substrate is then added  which results in the conversion of a colourless 
chrom ogen into a visible, coloured end product. The ABC techniques utilises the 
sensitive hydrogen peroxide-3,3’-diam inobenzidine (DAB) reaction which 
produces a brown end product which is insoluble in organic solvents. One 
draw back of this m ethod is that many types of b io log ica l tissue have 
endogenous levels of the enzyme peroxidase present tha t can  react in the final 
stage and produce high levels of non-specific staining. This has to be prevented 
by quenching the endogenous peroxidase activ ity with hydrogen peroxide 
before staining with the primary antibody.
Following this final stage, the tissue sections are m ounted on m icroscope slides, 
dehydra ted through increasing concentrations of a lcohol, c leared  in xylene and 
finally cover-slipped.
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Avidin-Biotin Complex
rat anti-5-HT 
primary antibody
biotinylated rabbit anti-rat 
secondary antibody
antigen (5-HT)
Figure A2.1. The ABC technique for immunohistochemistry as 
used in this study. A = avidin; B = biotin; P = peroxidase.
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Appendix 3: Densitometrical Analysis
The principle of densitometry is based on the fa c t tha t radiation, including light is 
lost as it passes through a medium. If we have a beam  of m onochrom atic light 
of rad iant pow er Po passing through a sample solution then absorption takes 
p lace  and the radiation leaving the sample has rad ian t pow er P. Beer's Law 
states tha t for transm ittance (T):
T = P/Po
and for absorbance (A):
A = logioPo/P
This radiation loss in a m edia is a function of the substance's molarity or 
concentration. According to Beer's law, concentra tion  is proportional to optica l 
density (OD). From this it is possible to use a scaling system for pixels in a 
photograph, which has a one to one correspondence with the concentration of 
a substance being studied. The logarithm ic optica l density scale and net integral 
of density values for an ob jec t in an im age is the proper measure for use in 
quantification. So by Beer's Law, the density of a point is the log ratio of incident 
light upon it and transmitted light through it:
OD = logioPo/P
There are several standard methods used to find the density of an ob jec t or a 
point on an im age. The one used in this study uses photom icrographs of the SCN 
taken a t X I0 m agnification and then digitised on a fla tbed  scanner. OD values
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a r e  n o t  m e a s u r e d  d i r e c t ly  b y  th is m e t h o d .  P ixel v a lu e s  in t h e  p h o t o g r a p h  a r e  
l in e a r  w ith  r e s p e c t  to  T, w h ic h  is t h e  a n t i - lo g  o f  t h e  n e g a t iv e  o f  O D :
T = 1 C K > D
T h e  s o f tw a r e  u s e d , S c io n  Im a g e ,  c a n  b e  c a l ib r a t e d  fo r  o p t ic a l  d e n s ity  
m e a s u r e m e n ts  u s in g  e x te r n a l  s ta n d a r d s . For s o m e  a p p l ic a t io n s ,  e x te r n a l  
s t a n d a r d s  a r e  a v a i la b le  fo r  k n o w n  c o n c e n t r a t io n s  o f  t h e  s u b s t a n c e  b e in g  
m e a s u r e d ,  w h ic h  a l lo w s  a c t u a l  m o la r  c o n c e n t r a t io n s  t o  b e  c a lc u l a t e d .  
U n f o r tu n a te ly  t h e r e  a r e  n o  s u c h  s ta n d a r d s  a v a i la b le  fo r  5 -H T  in n e rv o u s  tissue  
a n d  so  a  p h o t o g r a p h ic  s te p  t a b l e t  w a s  u s e d  (F ig u re  A 3 .1 ) .
Figure A3.1 Photographic step-tablet used for calibration of densitometry 
software
This o n ly  a llo w s  r e la t iv e  o p t ic a l  d e n s ity  (R O D )  to  b e  m e a s u r e d  r a th e r  t h a n  
a b s o lu te  v a lu e s . T h e  c a l ib r a t io n  p r o c e d u r e  a llo w s  t h e  t r a n s fo r m a t io n  o f  p ix e l 
v a lu e s  d ir e c t ly  f r o m  a  s c a le  t h a t  is l in e a r  w ith  r e s p e c t  to  T in to  a  s c a le  t h a t  
c o r r e la te s  to  O D  o r  c o n c e n t r a t io n .  A n  e q u a l  a r e a  o f  e a c h  o f  t h e  g r e y  b a n d s  o n  
t h e  s te p  t a b l e t  is m e a s u r e d  to  g iv e  a  m e a n  g r e y s c a le  v a lu e  fo r  t h a t  b a n d .  T h e s e  
v a lu e s  a r e  th e n  m a t c h e d  w ith  t h e  c o r r e s p o n d in g  k n o w n  o p t ic a l  d e n s it ie s  fo r  
e a c h  o f  t h e  b a n d s  to  p r o d u c e  a  c a l ib r a t io n  c u r v e  (F ig u re  A 3 .2 ) .  T h e  im a g e s  o f  
s a m p le  tissu e  a r e  th e n  lo a d e d  in to  t h e  s o f tw a r e  a n d  m e a s u r e m e n ts  t a k e n  o f  t h e  
r e g io n  o f  in te re s t . This g r e y s c a le  m e a s u r e m e n t  is th e n  c o n v e r t e d  t o  o p t ic a l  
d e n s ity  b y  c o m p a r is o n  w ith  th e  c a l ib r a t io n  c u r v e .
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20 f y=a+bx+cxA2+dxA3
a=-0.49910480 
b=0.11421986 
c=-0 00118387 
d=0.00000417
0.00
2550
Figure A3.2 Calibration curve for optica l density
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